Men Syndromes (men1, Men2a, Men2b)
Multiple Endocrine Neoplasia syndromes are inherited autosomal dominant disorders characterized by tumors of multiple endocrine glands: MEN1 involves parathyroid, pituitary, and pancreatic tumors; MEN2A involves medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia; and MEN2B involves medullary thyroid carcinoma, pheochromocytoma, and mucosal neuromas with a marfanoid habitus.
MEN Syndromes (MEN1, MEN2A, MEN2B)
Multiple Endocrine Neoplasia (MEN) syndromes are a group of inherited autosomal dominant disorders characterised by the occurrence of tumours (benign and/or malignant) in two or more endocrine glands in a single individual. The name itself tells you what's going on:
- "Multiple" = more than one
- "Endocrine" = hormone-producing glands
- "Neoplasia" = new, abnormal growth (tumours)
So fundamentally, these are genetic conditions where patients develop tumours across multiple endocrine organs — not by coincidence, but because of a germline mutation inherited from a parent (or rarely arising de novo) that predisposes every endocrine cell in the body to neoplastic transformation.
There are three classical subtypes:
| Syndrome | Also Known As | Core Gene |
|---|---|---|
| MEN1 | Wermer syndrome | MEN1 (encoding menin) |
| MEN2A | Sipple syndrome | RET proto-oncogene |
| MEN2B | MEN3 / Wagenmann-Froboese syndrome | RET proto-oncogene |
Key Concept
All MEN syndromes follow autosomal dominant inheritance. However, MEN1 and MEN2 involve fundamentally different genetic mechanisms: MEN1 is a tumour suppressor gene (loss-of-function, requires Knudson's "two-hit" model), while RET in MEN2 is a proto-oncogene (gain-of-function, a single activating mutation is sufficient). This distinction matters for understanding penetrance, screening, and prophylactic management.
2. Epidemiology
- Prevalence: ~2-3 per 100,000 [1]
- Incidence among endocrine tumour patients: 1-18% of parathyroid adenoma patients, 16-38% of gastrinoma patients, < 3% of pituitary adenoma patients [1]
- Equal male-to-female ratio (though some series show slight female predominance for pituitary tumours)
- Typical age of onset: 2nd–4th decade for primary hyperparathyroidism (earliest and most penetrant feature); almost 100% penetrance by age 40–50 years [1]
- MEN1 accounts for ~10% of all Zollinger-Ellison syndrome cases and ~4% of primary hyperparathyroidism cases
- Prevalence: ~2.4 per 100,000 [1]
- Accounts for ~75–80% of all MEN2 cases
- Medullary thyroid carcinoma (MTC) onset typically in the 3rd decade (i.e. 20–30 years old)
- Equal sex ratio for MTC component
- Prevalence: ~1 in 600,000 to 1 in 4,000,000 (extremely rare) [1]
- Accounts for ~5% of all MEN2 cases
- Earliest onset and most aggressive of the MEN syndromes — MTC can develop in infancy/early childhood
- ~50% of MEN2B cases are de novo mutations (no family history), making clinical vigilance critical
- MEN syndromes are rare in Hong Kong, as globally
- Genetic testing for RET mutations is available at major hospitals (e.g. QMH, PWH)
- Given the high prevalence of MTC in MEN2, the Hong Kong College of Surgeons and endocrine teams actively recommend cascade genetic screening of at-risk family members
- In Hong Kong, thyroid cancer overall is more common in females (~3:1 F:M), but the MTC component of MEN2 is ~1:1
Since MEN syndromes are genetic disorders, the overwhelmingly dominant risk factor is:
-
Family history / Germline mutation carrier status — the single most important risk factor
- First-degree relatives of a known MEN patient have a 50% chance of inheriting the mutation (autosomal dominant)
- This is why cascade genetic screening is essential
-
De novo mutations — particularly in MEN2B (~50% of cases), so lack of family history does NOT rule it out
-
Specific RET codon mutations — the specific codon mutated in RET determines the aggressiveness and clinical phenotype (see Classification section)
There are no significant environmental, dietary, or lifestyle risk factors for MEN syndromes — they are overwhelmingly genetically determined.
Exam Pearl
Unlike sporadic thyroid cancer (where female sex, radiation exposure, and FAP are risk factors), MEN-associated tumours are driven almost entirely by the germline mutation. However, remember that head and neck irradiation is a risk factor for sporadic parathyroid adenomas — which is a separate entity from MEN-associated parathyroid disease [2].
4. Anatomy and Function of Affected Organs
Understanding MEN syndromes requires knowing the embryology and function of each affected gland, because the pattern of organ involvement is NOT random — it reflects the developmental biology of the cells affected.
- Four glands (superior pair from 4th pharyngeal pouch, inferior pair from 3rd pharyngeal pouch)
- Located posterior to the thyroid gland
- Composed of chief cells (secrete PTH) and oxyphil cells (rich in mitochondria — this is why sestamibi scans work!)
- Function: PTH → ↑serum calcium by (1) ↑osteoclast bone resorption, (2) ↑renal Ca²⁺ reabsorption and ↓phosphate reabsorption, (3) ↑1α-hydroxylase activity → ↑1,25-dihydroxyvitamin D → ↑intestinal Ca²⁺ absorption
- In MEN1: typically multigland hyperplasia (all 4 glands) — not a single adenoma like sporadic disease [1][3]
- In MEN2A: also hyperplasia, but usually milder and often asymptomatic [1]
- Located in the sella turcica of the sphenoid bone
- Anterior pituitary (adenohypophysis) — derived from Rathke's pouch (oral ectoderm)
- Different cell types: lactotrophs (prolactin), somatotrophs (GH), corticotrophs (ACTH), thyrotrophs (TSH), gonadotrophs (LH/FSH)
- In MEN1: prolactinomas are most common (~60% of pituitary tumours), but GH-secreting, ACTH-secreting, and non-functioning adenomas also occur [1]
- MEN1-associated pituitary tumours tend to be larger (85% macroadenomas vs 42% in sporadic) and more aggressive than sporadic pituitary adenomas [1]
- Islets of Langerhans contain: α-cells (glucagon), β-cells (insulin), δ-cells (somatostatin), PP cells (pancreatic polypeptide), and ε-cells (ghrelin)
- Duodenal G cells produce gastrin
- In MEN1: pancreatic neuroendocrine tumours (pNETs) are frequently multifocal — this is why surgical cure is difficult and medical management (e.g. PPI for ZES) is often preferred [1][4]
- Common pNETs in MEN1: gastrinoma (most common functional, ~54% of MEN1 patients), insulinoma, VIPoma, glucagonoma, non-functioning pNETs [1]
- C cells (parafollicular cells) are derived from neural crest cells (NOT endoderm like follicular cells)
- This neural crest origin explains why C cell tumours (MTC) are associated with other neural crest-derived tumours (phaeochromocytoma, ganglioneuromas)
- C cells produce calcitonin (opposes PTH: ↓serum calcium by inhibiting osteoclasts)
- In MEN2: C cells undergo C-cell hyperplasia → medullary thyroid carcinoma (MTC)
- Adrenal medulla = modified sympathetic ganglion, composed of chromaffin cells (also neural crest-derived)
- Chromaffin cells synthesise catecholamines: tyrosine → DOPA → dopamine → noradrenaline → adrenaline (the last step requires PNMT, induced by cortisol from the adrenal cortex)
- In MEN2: chromaffin cells undergo hyperplasia → phaeochromocytoma
- Typically bilateral (30–100%) but less commonly extra-adrenal or malignant compared to sporadic cases [1]
- Usually secrete adrenaline (and noradrenaline), causing paroxysmal hypertension, headache, sweating, and palpitations
- Mucosal neuromas: benign tumours of nerve tissue on mucosal surfaces (lips, tongue, eyelids, GI tract)
- Intestinal ganglioneuromas: tumours of ganglion cells in the GI tract → can cause chronic constipation, megacolon
- Marfanoid habitus: tall, thin body habitus with long limbs, joint laxity, skeletal deformities — but NO aortic root abnormalities or ectopia lentis (differentiating from true Marfan syndrome, which involves fibrillin-1) [1]
- Myelinated corneal nerves: visible on slit-lamp examination
Why Neural Crest?
The unifying theme of MEN2 (especially MEN2B) is that RET is a receptor tyrosine kinase critical for neural crest cell development and survival. Constitutive activation of RET drives proliferation of neural crest-derived cells: C cells → MTC, chromaffin cells → phaeochromocytoma, ganglion cells → ganglioneuromas, Schwann cells/neurons → mucosal neuromas. This is why MEN2B has such a distinctive phenotype — it's fundamentally a disorder of neural crest-derived tissues.
5. Etiology and Pathophysiology
5.1 MEN1 — The Tumour Suppressor Story
- Encodes the protein menin (a 610-amino acid nuclear protein)
- Menin functions as a tumour suppressor — it normally acts as a brake on cell proliferation
Menin is involved in:
- Transcriptional regulation: interacts with JunD (a transcription factor) to suppress cell growth; also interacts with mixed lineage leukemia (MLL) protein to regulate chromatin remodelling and histone methylation
- Cell cycle control: helps maintain genomic stability
- TGF-β signalling: menin facilitates TGF-β-mediated growth inhibition
- DNA repair: involved in maintaining genomic integrity
- First hit: germline mutation inherited from a parent (present in every cell) — this alone is insufficient to cause a tumour
- Second hit: somatic mutation or loss of heterozygosity (LOH) of the remaining normal allele in an endocrine cell → complete loss of menin function → uncontrolled cell proliferation → tumour formation
- This explains:
- Why tumours are multifocal: each endocrine cell independently can undergo a second hit
- Why penetrance is variable: the second hit is stochastic (random)
- Why different organs are affected at different ages: some tissues are more susceptible to LOH than others
Over 1,500 different MEN1 mutations have been described — there is no clear genotype-phenotype correlation (unlike MEN2), meaning you cannot predict which tumours will develop based on the specific mutation.
| Tumour | Mechanism | Clinical Consequence |
|---|---|---|
| Parathyroid hyperplasia | Loss of menin → uncontrolled chief cell proliferation → ↑PTH → hypercalcaemia | Kidney stones, bone pain, polyuria, constipation, psychiatric symptoms ("bones, stones, abdominal moans, psychic groans") |
| Pituitary adenoma | Loss of menin → uncontrolled proliferation of anterior pituitary cells | Prolactinoma → galactorrhoea, amenorrhoea; GH adenoma → acromegaly; ACTH adenoma → Cushing's disease; mass effect → bitemporal hemianopia, headache |
| Pancreatic NETs | Loss of menin → islet cell proliferation | Gastrinoma → ZES (peptic ulcers, diarrhoea); insulinoma → hypoglycaemia; VIPoma → watery diarrhoea, hypokalaemia |
| Carcinoid tumours | Loss of menin in enterochromaffin cells | Thymic carcinoids (esp. in male smokers — aggressive), bronchial carcinoids, gastric carcinoids |
| Adrenocortical tumours | Loss of menin in adrenal cortical cells | Usually non-functional; rarely Cushing's or Conn's |
5.2 MEN2 — The Oncogene Story
- "RET" stands for "REarranged during Transfection" — it was discovered because of chromosomal rearrangement during experimental transfection
- Encodes a receptor tyrosine kinase (RTK) expressed on neural crest-derived cells
- Normal function: RET is activated by glial cell line-derived neurotrophic factor (GDNF) family ligands → promotes cell survival, differentiation, and proliferation during embryonic development (particularly of neural crest cells, kidneys, and enteric nervous system)
- Unlike MEN1, RET mutations in MEN2 are activating (gain-of-function) mutations
- A single missense mutation is sufficient to constitutively activate the RET receptor without ligand binding → continuous, unregulated intracellular signalling → uncontrolled proliferation of neural crest-derived cells
- This is why MEN2 follows a dominant oncogene model — only one mutant allele is needed (no "second hit" required)
- Key downstream pathways activated: RAS/MAPK, PI3K/AKT, PLCγ, JAK/STAT → cell survival, proliferation, and migration
This is a critical concept for MEN2 and very different from MEN1. The specific codon mutated in RET determines:
- Which clinical subtype (MEN2A vs MEN2B)
- The aggressiveness of MTC
- The timing of prophylactic thyroidectomy
| RET Mutation | Syndrome | ATA Risk Level (2015) | Recommended Thyroidectomy Timing |
|---|---|---|---|
| Codon 634 (Cys634Arg) | MEN2A (most common) | High | By age 5 years |
| Codons 609, 611, 618, 620 | MEN2A | Moderate | Consider by age 5; can delay if calcitonin normal |
| Codon 804, 891 | MEN2A (FMTC variant) | Moderate | Can monitor with calcitonin |
| Codon 918 (Met918Thr) | MEN2B | Highest | Within first 6 months of life |
| Codon 883 | MEN2B | Highest | Within first year of life |
Exam High Yield: RET Codon 918
Codon 918 (M918T) is THE classic MEN2B mutation. It causes the most aggressive MTC with the earliest onset. Prophylactic thyroidectomy should be performed within the first 6 months of life — some guidelines even recommend within the first weeks/months. This is the highest-risk category in the ATA 2015 classification. Missing this diagnosis in an infant with mucosal neuromas and Marfanoid features can be fatal.
| Tumour | Mechanism | Clinical Consequence |
|---|---|---|
| MTC | Constitutive RET activation → C-cell hyperplasia → MTC | Neck mass, diarrhoea (calcitonin stimulates intestinal secretion), flushing, ↑calcitonin/CEA |
| Phaeochromocytoma | Constitutive RET activation → chromaffin cell hyperplasia → phaeochromocytoma | Paroxysmal HTN, headache, sweating, palpitations, pallor (the 5 P's) |
| Parathyroid hyperplasia (MEN2A only) | RET activation in parathyroid cells → hyperplasia | Usually mild hypercalcaemia, often asymptomatic |
| Mucosal neuromas (MEN2B only) | RET activation in Schwann cells/neurons → neural proliferation | Bumpy lips and tongue, thickened eyelids, corneal nerve thickening |
| Intestinal ganglioneuromas (MEN2B only) | RET activation in enteric ganglion cells | Constipation, megacolon, abdominal distension |
| Marfanoid habitus (MEN2B only) | RET effects on connective tissue/skeletal development | Tall, thin, long arms/legs, joint laxity, but NO lens subluxation or aortic root dilatation |
This is a commonly asked question. The answer lies in the differential sensitivity of cell types to RET activation:
- C cells appear to be more sensitive to constitutive RET signalling than chromaffin cells
- MTC typically develops in the 2nd–3rd decade in MEN2A, while phaeochromocytoma develops later (mean age 25–32 years) [1]
- In MEN2B, MTC can develop even in infancy, while phaeochromocytoma still typically appears later
- This temporal sequence is clinically important: always screen for and exclude phaeochromocytoma before operating on MTC — operating on a patient with an undiagnosed phaeo can trigger a life-threatening hypertensive crisis under anaesthesia
6. Classification
The three main subtypes are: [1][2]
| Feature | MEN1 | MEN2A | MEN2B |
|---|---|---|---|
| Alternate name | Wermer syndrome | Sipple syndrome | MEN3 / Wagenmann-Froboese |
| Gene | MEN1 (menin) at 11q13 | RET proto-oncogene at ch10 | RET proto-oncogene at ch10 |
| Mechanism | Loss of function (tumour suppressor) | Gain of function (oncogene) | Gain of function (oncogene) |
| Inheritance | Autosomal dominant | Autosomal dominant | Autosomal dominant (~50% de novo) |
| Tumour 1 | Parathyroid hyperplasia (95–100%) | Medullary thyroid carcinoma (virtually 100%) | Medullary thyroid carcinoma (virtually 100%) |
| Tumour 2 | Pituitary adenoma (15–42%) | Phaeochromocytoma (~50%) | Phaeochromocytoma (~50%) |
| Tumour 3 | Pancreatic NETs (30–80%) | Parathyroid hyperplasia (10–25%) | Mucosal neuromas |
| Other features | Carcinoid tumours, cutaneous tumours (angiofibromas, collagenomas), adrenocortical tumours | Cutaneous lichen amyloidosis, Hirschsprung disease | Intestinal ganglioneuromas, Marfanoid habitus (but no aortic abnormalities or ectopia lentis) |
Parathyroid (hyperplasia) — "Bones, stones, abdominal moans, psychic groans" Pancreatic NETs (gastrinoma, insulinoma, VIPoma, etc.) Pituitary adenoma (prolactinoma most common)
| Feature | MEN2A | MEN2B |
|---|---|---|
| Parathyroid disease | Yes (10-25%) | No |
| Mucosal neuromas | No | Yes (pathognomonic) |
| Marfanoid habitus | No | Yes |
| Intestinal ganglioneuromas | No | Yes |
| Hirschsprung disease | Yes (rare) | No (but may have colonic dysfunction) |
| Cutaneous lichen amyloidosis | Yes (rare) | No |
| MTC aggressiveness | Less aggressive | Most aggressive |
| Age of MTC onset | 2nd–3rd decade | Infancy–childhood |
- Previously classified as a separate entity, FMTC is now considered a variant of MEN2A with MTC as the only manifestation (i.e. no phaeochromocytoma or hyperparathyroidism)
- Associated with lower-risk RET mutations (codons 804, 891)
- Clinical significance: families diagnosed with "FMTC" should still be screened for phaeochromocytoma and hyperparathyroidism, as these may appear later in life
The American Thyroid Association (ATA) classifies RET mutations into risk categories that guide the timing of prophylactic thyroidectomy:
| ATA Risk Category | RET Mutation(s) | Estimated MTC Onset | Prophylactic Thyroidectomy Timing |
|---|---|---|---|
| Highest | 918 (M918T) — MEN2B | Infancy | Within first 6 months of life |
| High | 634 (C634R) — MEN2A | Childhood | By age 5 years |
| Moderate | 609, 611, 618, 620, 630, 804, 891 | Variable, later | Can consider monitoring with annual calcitonin; thyroidectomy by age 5 or when calcitonin rises |
Clinical Pearl: Prophylactic Thyroidectomy
Prophylactic total thyroidectomy is indicated for all patients with RET mutations since virtually all patients develop clinically apparent MTC [2]. The timing depends on the specific mutation and ATA risk category. This is one of the few situations in medicine where we recommend organ removal in a patient who currently has no disease.
7. Clinical Features
The clinical features of MEN syndromes are essentially the sum of the individual tumour manifestations. The key clinical skill is pattern recognition — seeing a cluster of endocrine tumours in one patient (or family) should trigger MEN screening.
7.1 MEN1 Clinical Features
i. Primary Hyperparathyroidism (earliest and most common, 95–100%)
- Polyuria and polydipsia — hypercalcaemia impairs renal concentrating ability (↓aquaporin-2 expression in collecting ducts → nephrogenic diabetes insipidus)
- Renal colic / flank pain — calcium phosphate / calcium oxalate stones form due to hypercalciuria
- Bone pain / fragility fractures — chronically elevated PTH → ↑osteoclast activity → bone resorption → osteoporosis / osteitis fibrosa cystica
- Abdominal pain / constipation — hypercalcaemia → ↓smooth muscle contractility in GI tract; also pancreatitis (calcium activates trypsinogen)
- Psychiatric symptoms — depression, confusion, cognitive impairment ("psychic groans") — calcium affects neuronal membrane excitability
- Nausea / anorexia — direct CNS and GI effects of hypercalcaemia
- Muscle weakness / fatigue — hypercalcaemia disrupts neuromuscular junction transmission
Mnemonic for hypercalcaemia: "Bones, stones, abdominal moans, and psychic groans"
ii. Pituitary Adenoma (15–42%)
- Prolactinoma (most common, ~60% of MEN1 pituitary tumours):
- Women: galactorrhoea (prolactin stimulates breast milk production), amenorrhoea/oligomenorrhoea (prolactin suppresses GnRH → ↓LH/FSH), infertility
- Men: erectile dysfunction, decreased libido, gynecomastia (often diagnosed later because symptoms are subtler → more commonly macroadenomas in men)
- GH-secreting adenoma: features of acromegaly — enlarged hands/feet, coarsened facial features, prognathism, excessive sweating, carpal tunnel syndrome, obstructive sleep apnoea
- ACTH-secreting adenoma: features of Cushing's disease — central obesity, moon face, buffalo hump, purple striae, proximal myopathy, hypertension, diabetes, easy bruising
- Non-functioning adenoma: mass effect only
- Mass effect (especially macroadenomas, which are more common in MEN1):
- Bitemporal hemianopia — tumour compresses the optic chiasm from below
- Headache — stretching of the diaphragma sellae
- Hypopituitarism — compression of normal pituitary tissue → sequential loss of GH > LH/FSH > TSH > ACTH (in that order due to differential sensitivity)
iii. Pancreatic/Duodenal Neuroendocrine Tumours (30–80%)
-
Gastrinoma / Zollinger-Ellison Syndrome (most common functional pNET in MEN1, ~54%):
- Epigastric pain — multiple peptic ulcers in unusual locations (distal duodenum, jejunum) due to massive gastric acid hypersecretion (gastrin → parietal cell stimulation → 4-6× normal acid output) [4]
- Chronic diarrhoea — (1) overwhelming acid inactivates pancreatic lipase → steatorrhoea; (2) acid damages small bowel mucosa → malabsorption; (3) hypergastrinaemia inhibits Na⁺/H₂O reabsorption [4]
- Heartburn / reflux oesophagitis — from acid excess
- GI bleeding — from multiple erosive ulcers
- Weight loss — from malabsorption and chronic diarrhoea
-
Insulinoma (~10% of MEN1 patients):
- Neuroglycopenic symptoms: confusion, blurred vision, seizures, loss of consciousness — brain depends on glucose and is first to suffer
- Autonomic/adrenergic symptoms: tremor, sweating, palpitations, hunger — catecholamine counter-regulatory response to hypoglycaemia
- Whipple's triad: (1) symptoms of hypoglycaemia, (2) documented low blood glucose during symptoms, (3) resolution of symptoms with glucose administration
- Symptoms typically occur fasting or post-exercise
-
VIPoma (rare):
- Watery diarrhoea (profuse, secretory, up to 3-5 L/day) — VIP stimulates intestinal chloride and water secretion
- Hypokalaemia — massive faecal potassium losses
- Achlorhydria — VIP inhibits gastric acid secretion (Verner-Morrison syndrome = "pancreatic cholera")
-
Glucagonoma (rare):
- Necrolytic migratory erythema — characteristic skin rash (pathognomonic); pathogenesis involves amino acid deficiency and zinc/fatty acid deficiency from glucagon-induced catabolism
- Diabetes mellitus — glucagon is a counter-regulatory hormone that ↑hepatic gluconeogenesis and glycogenolysis
- DVT — glucagon promotes a hypercoagulable state
- Depression — mechanism not fully understood
-
Non-functioning pNETs (20–55%): often detected incidentally on imaging; may cause symptoms from mass effect (abdominal pain, biliary obstruction)
iv. Other Tumours
- Thymic carcinoids: particularly in male smokers — can be aggressive; cervical thymectomy during parathyroidectomy may reduce risk
- Bronchial carcinoids: usually indolent
- Cutaneous lesions: often present before endocrine tumours manifest — can be an early diagnostic clue
i. Signs of Hyperparathyroidism / Hypercalcaemia
- Band keratopathy — calcium deposits in the cornea (medial and lateral limbus)
- Shortened QTc interval on ECG — calcium accelerates cardiac repolarization
- Hypertension — chronic hypercalcaemia causes vasoconstriction and direct smooth muscle calcium entry
- Proximal muscle weakness — hypercalcaemia impairs neuromuscular junction
ii. Signs of Pituitary Tumour
- Visual field defect (bitemporal hemianopia) — optic chiasm compression
- Galactorrhoea (expressible or spontaneous)
- Signs of acromegaly: large hands and feet, prognathism, frontal bossing, skin tags, macroglossia
- Signs of Cushing's disease: central obesity, moon face, buffalo hump, thin skin, purple striae, proximal myopathy
- Hypogonadism signs: in men — gynaecomastia, testicular atrophy; in women — absent secondary sexual characteristics (if prepubertal onset)
iii. Signs of Pancreatic NETs
- Epigastric tenderness (ZES — ulcer disease)
- Signs of hepatomegaly (if liver metastases — especially gastrinoma, 60-90% malignant)
- Necrolytic migratory erythema — annular, erythematous, blistering skin lesions that migrate, often on perineum, groin, buttocks, and lower extremities (glucagonoma)
iv. Cutaneous Signs (can be an early clue!)
- Angiofibromas (64% of MEN1 patients): small, skin-coloured to red papules on the face — resemble fibrous papules [1]
- Collagenomas (62%): skin-coloured, firm, subcutaneous plaques on the trunk [1]
- These cutaneous findings may precede endocrine tumour diagnosis and should prompt MEN1 screening
7.2 MEN2A Clinical Features
i. Medullary Thyroid Carcinoma (virtually 100%)
- Palpable thyroid nodule — typically bilateral, multicentric (cf. sporadic MTC which is unilateral) [5]
- Cervical lymphadenopathy — MTC spreads via lymphatics early; level VI nodes (central compartment) are the first site of metastasis [5]
- Diarrhoea (30% of patients) — calcitonin directly stimulates intestinal chloride and water secretion → secretory diarrhoea; this can be the presenting symptom
- Flushing — calcitonin and other peptides (prostaglandins, CGRP) cause vasodilatation
- Bone pain (if distant metastases)
- Hoarseness — recurrent laryngeal nerve invasion (suggests locally advanced disease)
- Dysphagia / dyspnoea — compression or invasion of trachea/oesophagus (late features)
ii. Phaeochromocytoma (~50% in MEN2A)
- Classic triad: paroxysmal headache, sweating, and palpitations [3]
- Paroxysmal hypertension — catecholamines (adrenaline and noradrenaline) cause vasoconstriction (α₁ receptors) and ↑heart rate/contractility (β₁ receptors)
- Postural hypotension (paradoxically) — chronic catecholamine excess → plasma volume contraction + desensitisation of adrenergic receptors
- Anxiety / panic attacks — adrenaline activates central and peripheral adrenergic pathways
- Pallor (NOT flushing) — α₁-mediated cutaneous vasoconstriction ("the 5th P of Phaeo")
- Weight loss — catecholamines increase basal metabolic rate
- Glucose intolerance / diabetes — catecholamines promote glycogenolysis and gluconeogenesis and inhibit insulin secretion
Mnemonic: The 5 P's of Phaeochromocytoma: Pressure (HTN), Pain (headache, chest pain), Palpitation, Perspiration, Pallor [3]
iii. Primary Hyperparathyroidism (10–25%)
- Usually mild and asymptomatic [1]
- When symptomatic: same features as MEN1 hyperparathyroidism (stones, bones, moans, groans) but typically milder
iv. Cutaneous Lichen Amyloidosis (rare but characteristic)
- Pruritic, pigmented, lichenoid skin lesion — typically over the upper back (interscapular region)
- Pathogenesis: amyloid deposits derived from keratin in the papillary dermis
- Associated with specific RET codon 634 mutations
v. Hirschsprung Disease (rare)
- Constipation, abdominal distension, failure to thrive in neonates/infants
- Pathogenesis: RET is essential for enteric nervous system development; certain RET mutations paradoxically cause both gain-of-function (in C cells) and loss-of-function (in enteric neurons) — hence Hirschsprung disease and MEN2A can coexist
- Thyroid mass: firm, non-tender, may be bilateral; may have palpable cervical lymphadenopathy (level VI, lateral neck)
- Hypertension (if phaeochromocytoma) — may be sustained or paroxysmal
- Tachycardia, tremor — catecholamine excess
- Orthostatic hypotension — volume depletion from chronic catecholamine excess
- Pallor during hypertensive paroxysms
- Retinal changes — hypertensive retinopathy if chronic HTN
- Interscapular pigmented pruritic plaques — cutaneous lichen amyloidosis (MEN2A with codon 634)
7.3 MEN2B Clinical Features
i. Medullary Thyroid Carcinoma (virtually 100%)
- Same symptoms as MEN2A but earlier onset (infancy/childhood) and more aggressive [1]
- MTC in MEN2B has the worst prognosis of all MEN-associated MTCs
- May already have lymph node and distant metastases at diagnosis in childhood
ii. Phaeochromocytoma (~50%)
- Same as MEN2A (5 P's)
iii. Mucosal Neuromas (pathognomonic for MEN2B)
- Typically involves lips and tongue [1]
- Bumpy, nodular lips — visible as small, glistening nodules on the vermilion border of the lips
- Enlarged, nodular tongue — nodules of neural tissue
- Thickened eyelids — neuromas on eyelid margins → everted eyelids (can resemble blepharochalasis)
- These may be present from birth or early infancy — often the FIRST clinical sign of MEN2B and should trigger immediate RET genetic testing
iv. Intestinal Ganglioneuromas
- Chronic constipation — ganglioneuromas in the intestinal wall disrupt normal peristalsis [1]
- Megacolon — chronic functional obstruction due to dysmotile bowel
- Abdominal distension, bloating
- Failure to thrive in children — from chronic GI dysmotility and poor feeding
v. Skeletal / Developmental
- Marfanoid habitus: tall stature, long limbs, arm span > height, long fingers (arachnodactyly)
- BUT: no ectopia lentis (lens subluxation) and no aortic root abnormalities — this differentiates from true Marfan syndrome (FBN1 mutation) [1]
- Joint laxity
- Skeletal deformities: kyphosis, scoliosis, pes cavus
- ↓Upper-to-lower body ratio (long limbs relative to trunk) [1]
vi. Ocular
- Myelinated corneal nerves — visible on slit-lamp examination as prominent white nerve fibres on the cornea
- Dry eyes — neuronal dysfunction
- Prominent, thickened eyelid margins from mucosal neuromas
- Mucosal neuromas: glistening nodules on lips, tongue, buccal mucosa, conjunctivae — often the most striking and recognisable finding on examination
- Marfanoid habitus: tall, thin, long limbs, joint laxity
- Thyroid mass (bilateral, firm)
- Cervical lymphadenopathy
- Hypertension (if phaeo present)
- Abdominal distension (if ganglioneuromas causing megacolon)
- Myelinated corneal nerves on slit-lamp exam
- Skeletal deformities
Clinical Pearl: Recognising MEN2B in a Child
If you see a child with bumpy lips, a thick tongue, a Marfanoid body habitus, and constipation — think MEN2B immediately. These physical findings often precede the diagnosis of MTC. Since ~50% of MEN2B cases are de novo mutations (no family history), the phenotypic recognition is the KEY to early diagnosis. Missing this diagnosis means missing the window for prophylactic thyroidectomy, which should ideally be done within the first 6 months of life.
| Clinical Feature | MEN1 | MEN2A | MEN2B |
|---|---|---|---|
| Hyperparathyroidism | +++ (95-100%) | + (10-25%, mild) | − |
| Pituitary adenoma | ++ (15-42%) | − | − |
| Pancreatic NETs | ++ (30-80%) | − | − |
| MTC | − | +++ (virtually 100%) | +++ (virtually 100%, earliest and most aggressive) |
| Phaeochromocytoma | − | ++ (~50%) | ++ (~50%) |
| Mucosal neuromas | − | − | +++ (pathognomonic) |
| Intestinal ganglioneuromas | − | − | ++ |
| Marfanoid habitus | − | − | ++ |
| Cutaneous lichen amyloidosis | − | + (rare, codon 634) | − |
| Hirschsprung disease | − | + (rare) | − |
| Angiofibromas/collagenomas | ++ | − | − |
| Carcinoid tumours | + | − | − |
Since MEN syndromes are genetic, screening of at-risk family members is a core part of management. This will be detailed further in the Diagnosis section, but the clinical approach to a suspected MEN patient involves:
- Index case identification: pattern of endocrine tumours (≥2 MEN-associated tumours in one patient)
- Genetic testing: for MEN1 gene or RET proto-oncogene mutations
- Cascade screening: test all first-degree relatives
- Biochemical and imaging surveillance: tailored to syndrome type and mutation risk category
- Prophylactic surgery: particularly thyroidectomy in MEN2 mutation carriers
High Yield Summary
MEN1 (Wermer syndrome):
- Gene: MEN1 (menin), chromosome 11q13, tumour suppressor, autosomal dominant, Knudson two-hit model
- 3 P's: Parathyroid hyperplasia (95-100%), Pancreatic NETs (gastrinoma most common functional), Pituitary adenoma (prolactinoma most common)
- Also: carcinoid tumours, angiofibromas, collagenomas, adrenocortical tumours
- Almost 100% penetrance for hyperparathyroidism by age 40-50
- No genotype-phenotype correlation
MEN2A (Sipple syndrome):
- Gene: RET proto-oncogene, chromosome 10, gain-of-function, autosomal dominant
- MTC (virtually 100%) + Phaeochromocytoma (~50%) + Parathyroid hyperplasia (10-25%)
- Also: cutaneous lichen amyloidosis, Hirschsprung disease
- Codon 634 = most common mutation = high risk
MEN2B (MEN3):
- Gene: RET proto-oncogene (codon 918 most common), ~50% de novo
- MTC (virtually 100%, most aggressive) + Phaeochromocytoma (~50%) + Mucosal neuromas + Intestinal ganglioneuromas + Marfanoid habitus
- NO parathyroid disease (unlike MEN2A)
- Marfanoid but NO ectopia lentis or aortic root pathology
- Prophylactic thyroidectomy within first 6 months of life
Key Rule for MEN2: Always screen for and exclude phaeochromocytoma BEFORE any surgery (thyroidectomy or otherwise) — undiagnosed phaeo under anaesthesia can be fatal.
Genetic Testing: MEN1 = no genotype-phenotype correlation; MEN2 = strong genotype-phenotype correlation guiding timing of prophylactic thyroidectomy.
Active Recall - MEN Syndromes (Definition, Epidemiology, Etiology, Pathophysiology, Classification, Clinical Features)
[1] Senior notes: Ryan Ho Endocrine.pdf (pages 38, 100, 102, 132–133) [2] Senior notes: felixlai.md (Etiology section — MEN table and thyroid cancer risk factors) [3] Senior notes: maxim.md (Phaeochromocytoma section, Primary hyperparathyroidism section, Adrenal incidentaloma section) [4] Senior notes: maxim.md (Gastrinoma / Zollinger-Ellison syndrome section, Insulinoma section) [5] Senior notes: Ryan Ho Endocrine.pdf (page 38 — Medullary thyroid carcinoma) [6] Senior notes: Ryan Ho Chemical Path.pdf (page 23 — Hypercalcaemia workup and MEN) [7] Senior notes: Ryan Ho Diagnostic Radiology.pdf (page 72 — Functional imaging for adrenal tumours, phaeochromocytoma)
Differential Diagnosis of MEN Syndromes
The clinical challenge with MEN syndromes is that patients rarely walk in saying "I have MEN." Instead, they present with one component tumour — a parathyroid adenoma, a thyroid nodule, a pancreatic NET, a phaeochromocytoma, or even just refractory peptic ulcer disease. The differential diagnosis therefore operates on two levels:
-
Level 1 — "Is this endocrine tumour sporadic or part of a hereditary syndrome?" This is the most critical question. Most endocrine tumours are sporadic. MEN should be suspected when there are multiple endocrine tumours, young age at presentation, bilateral/multifocal disease, or a positive family history.
-
Level 2 — "If hereditary, which syndrome is it?" Once you suspect a hereditary cause, you need to differentiate between MEN1, MEN2A, MEN2B, and the other hereditary tumour syndromes that can mimic MEN.
The logic is: recognise the pattern → suspect the syndrome → confirm genetically.
9.1 Differential Diagnosis by Presenting Component
Because MEN patients present with individual tumour components, let's work through the DDx from each common entry point.
The vast majority of primary hyperparathyroidism (PHPT) is sporadic (~95%). But certain red flags should prompt consideration of a hereditary syndrome:
| Diagnosis | Key Distinguishing Features | Why It Mimics MEN |
|---|---|---|
| Sporadic parathyroid adenoma (80% of PHPT) | Single gland, older age (postmenopausal women), no FHx | Most common cause of PHPT; a single adenoma does NOT equal MEN |
| MEN1 | Multigland hyperplasia, young onset (2nd–4th decade), FHx, concurrent pituitary/pancreatic tumours | Hyperparathyroidism is the earliest and most penetrant feature [1] |
| MEN2A | Mild, often asymptomatic hyperparathyroidism with concurrent MTC and/or phaeochromocytoma | Usually discovered during MEN2A workup, not the presenting feature [1] |
| Familial Hypocalciuric Hypercalcaemia (FHH) | Hypercalcaemia + normal/mildly elevated PTH + low urine calcium (Ca:Cr clearance ratio < 0.01); CaSR mutation | Mimics PHPT biochemically but does NOT require surgery; must check 24h urine Ca to rule out [3] |
| Familial isolated hyperparathyroidism (FIHP) | PHPT without other MEN features; may carry MEN1, CDC73 (HRPT2), or CaSR mutations | May be an incomplete expression of MEN1 or a distinct entity |
| Hyperparathyroidism–jaw tumour syndrome (HPT-JT) | PHPT + ossifying fibromas of the jaw + renal cysts/hamartomas; CDC73 (HRPT2) gene mutation | Higher risk of parathyroid carcinoma (~15%) unlike MEN where carcinoma is rare |
Exam Pearl: FHH vs PHPT
24h urine calcium is a must-check investigation in any patient with hypercalcaemia and elevated/normal PTH [3]. FHH has low urinary calcium (Ca:Cr clearance ratio < 0.01) because the mutated calcium-sensing receptor in the kidney fails to detect high serum calcium and inappropriately reabsorbs it. Operating on FHH patients is futile and harmful — parathyroidectomy will not correct the hypercalcaemia.
~20% of MTC is familial — every single MTC patient should be tested for RET mutation [5][8].
| Diagnosis | Key Distinguishing Features |
|---|---|
| Sporadic MTC (80%) | Unilateral, older age ( > 50y), no FHx, no associated tumours [1] |
| MEN2A | Bilateral, multifocal MTC + phaeochromocytoma (50%) + parathyroid hyperplasia (10–25%); RET codon 634 most common [1] |
| MEN2B | Bilateral, multifocal, earliest and most aggressive MTC + phaeochromocytoma (50%) + mucosal neuromas + Marfanoid habitus + intestinal ganglioneuromas; RET codon 918; ~50% de novo [1] |
| Familial MTC (FMTC) | MTC only (no phaeo or PHPT); now classified as a variant of MEN2A with lower-risk RET mutations (codons 804, 891); must continue surveillance for other MEN2A components |
FHx of thyroid CA: ~20% of medullary CA (MEN II), ~5% of papillary CA [8]
This is a critical differential because phaeochromocytoma is a feature of multiple hereditary syndromes, not just MEN2. Up to 40% of phaeochromocytomas are now considered familial — the old "10% familial" rule is outdated [1][7].
| Diagnosis | Gene | Key Distinguishing Features |
|---|---|---|
| Sporadic phaeochromocytoma | None | Most common; older age; usually unilateral, adrenal |
| MEN2A/2B | RET | Bilateral adrenal phaeo (30–100%) + MTC ± PHPT (2A) or mucosal neuromas (2B); less commonly extra-adrenal or malignant than sporadic [1] |
| Von Hippel-Lindau disease (VHL) | VHL | Phaeo (10–20%) + retinal and cerebellar haemangioblastomas + clear cell renal cell carcinoma + pancreatic cysts/NETs + endolymphatic sac tumours [7] |
| Neurofibromatosis type 1 (NF1) | NF1 | Phaeo (2–3%) + café-au-lait spots + neurofibromas + Lisch nodules + axillary/inguinal freckling + skeletal dysplasia [7][9] |
| Familial paraganglioma syndromes (PGL 1–4) | SDHx (SDHB, SDHC, SDHD, SDHA) | Head & neck paragangliomas + extra-adrenal sympathetic paragangliomas; SDHB mutations carry highest malignancy risk (~40%); succinate dehydrogenase mutations [3][7] |
| Carney triad | Sporadic (not hereditary) | GIST + pulmonary chondroma + paragangliomas; young women; distinct from Carney complex [3] |
| Carney-Stratakis syndrome | SDHB/SDHC/SDHD | GIST + paraganglioma; inherited (AD); no pulmonary chondroma (distinguishes from Carney triad) |
The New 40% Rule
The traditional "10% rule" for phaeochromocytoma (10% bilateral, 10% familial, 10% extra-adrenal, 10% malignant, etc.) is now outdated. Up to 40% are familial [1]. Current guidelines recommend genetic testing for ALL patients with phaeochromocytoma/paraganglioma, regardless of age or family history. The hereditary syndromes to consider are: MEN2, VHL, NF1, SDHx mutations, and Carney triad/Carney-Stratakis.
Most pituitary adenomas are sporadic. MEN1 accounts for < 3% of pituitary adenomas [1]. However, MEN1-associated pituitary tumours tend to be larger (85% macroadenomas) and more treatment-resistant.
| Diagnosis | Key Distinguishing Features |
|---|---|
| Sporadic pituitary adenoma | Most common; isolated; no FHx; microadenoma more common (~58%) |
| MEN1 | 85% macroadenoma (vs 42% sporadic); young onset; concurrent PHPT/pNETs; prolactinoma most common [1] |
| Familial isolated pituitary adenoma (FIPA) | AIP gene mutations; isolated pituitary adenomas in ≥2 family members without other MEN1 features; typically GH-secreting (somatotrophinomas) in young males |
| Carney complex | PRKAR1A gene mutation; pituitary adenoma (GH-secreting) + primary pigmented nodular adrenocortical disease (PPNAD/Cushing's) + cardiac myxomas + skin pigmentation (lentigines, blue naevi) |
| McCune-Albright syndrome | Somatic GNAS1 mutation → constitutive G-protein activation [10]; precocious puberty + café-au-lait spots ("Coast of Maine" borders) + polyostotic fibrous dysplasia; GH-secreting pituitary adenoma possible; NOT inherited (somatic mosaicism) |
| Diagnosis | Key Distinguishing Features |
|---|---|
| Sporadic pNET | Single tumour; older age; no FHx |
| MEN1 | Multiple, multifocal pNETs; young onset; concurrent PHPT/pituitary adenoma; gastrinoma most common functional type (~54%); if multiple insulinomas → consider MEN1 [4] |
| Von Hippel-Lindau disease | Pancreatic cysts and NETs + haemangioblastomas + RCC |
| Tuberous sclerosis complex (TSC) | Pancreatic NETs (rare) + cortical tubers + subependymal giant cell astrocytomas + renal angiomyolipomas + cardiac rhabdomyomas + skin findings (ash-leaf macules, shagreen patch, facial angiofibromas) |
| Neurofibromatosis type 1 | Duodenal somatostatinomas (periampullary); + NF1 features (café-au-lait, neurofibromas) |
This is particularly relevant for MEN2B differential:
| Diagnosis | Key Distinguishing Features |
|---|---|
| MEN2B | Marfanoid habitus + mucosal neuromas + MTC + phaeo + intestinal ganglioneuromas; NO ectopia lentis, NO aortic root pathology [1] |
| Marfan syndrome | FBN1 mutation; Marfanoid habitus + ectopia lentis (upward lens subluxation, ~60%) + aortic root dilatation/dissection + MVP; NO mucosal neuromas [10] |
| Homocystinuria | CBS deficiency; Marfanoid habitus + downward lens subluxation + intellectual disability + thromboembolism + osteoporosis; urine homocysteine elevated |
| Loeys-Dietz syndrome | TGFBR1/2 mutations; Marfanoid features + arterial tortuosity and aneurysms (widespread, not just aortic root) + bifid uvula/cleft palate + hypertelorism |
This is the core exam question — "given this cluster of tumours, which MEN syndrome is it?"
| Feature | MEN1 | MEN2A | MEN2B |
|---|---|---|---|
| Gene | MEN1 (menin) | RET | RET |
| Mechanism | Tumour suppressor (two-hit) | Oncogene (gain-of-function) | Oncogene (gain-of-function) |
| PHPT | +++ (95–100%) | + (10–25%) | − |
| Pituitary adenoma | ++ (15–42%) | − | − |
| Pancreatic NETs | ++ (30–80%) | − | − |
| MTC | − | +++ (100%) | +++ (100%, most aggressive) |
| Phaeochromocytoma | − | ++ (~50%) | ++ (~50%) |
| Mucosal neuromas | − | − | +++ (pathognomonic) |
| Marfanoid habitus | − | − | ++ |
| Intestinal ganglioneuromas | − | − | ++ |
| Hirschsprung disease | − | + (rare) | − |
| Cutaneous lichen amyloidosis | − | + (rare, codon 634) | − |
| Angiofibromas/collagenomas | ++ | − | − |
The Decisive Differentiators
- Pituitary adenoma or pancreatic NET present? → Think MEN1 (these NEVER occur in MEN2)
- MTC present? → Think MEN2 (MTC NEVER occurs in MEN1)
- Mucosal neuromas or Marfanoid habitus? → MEN2B specifically (never in MEN2A)
- Parathyroid disease + MTC + phaeo but NO neuromas? → MEN2A
- MTC + phaeo + neuromas but NO parathyroid disease? → MEN2B
This is a high-yield comparison because the exam loves to test whether you can distinguish these genetic syndromes:
| Syndrome | Gene | Phaeo Features | Unique Associated Tumours | Distinguishing Clue |
|---|---|---|---|---|
| MEN2 | RET | Bilateral adrenal; less extra-adrenal/malignant | MTC (100%), ± PHPT | Thyroid neck mass + hypertensive spells |
| VHL | VHL | Often bilateral; noradrenergic (NA-secreting → sustained HTN) | Retinal/cerebellar haemangioblastomas, clear cell RCC, pancreatic cysts | Young patient with retinal/CNS tumours + RCC + phaeo |
| NF1 | NF1 | Usually unilateral adrenal; rare (2–3%) | Café-au-lait spots, neurofibromas, Lisch nodules, optic glioma, skeletal dysplasia | Skin findings are obvious — NF1 diagnosed clinically (CAFESPOT criteria) [9] |
| SDHx / PGL syndromes | SDHB/C/D | Extra-adrenal (H&N paragangliomas common); SDHB = high malignancy risk | H&N paragangliomas, GIST (Carney-Stratakis) | H&N mass with catecholamine excess |
| Carney triad | Sporadic | Paragangliomas | GIST + pulmonary chondroma | Young woman with GI and lung masses + paraganglioma [3] |
In clinical practice (and exam scenarios), you should think about MEN in these situations:
Triggers for MEN1 screening:
- Primary hyperparathyroidism at young age (< 40 years) or with multigland disease
- Multiple insulinomas → consider MEN1 [4]
- Gastrinoma / Zollinger-Ellison syndrome (20-30% associated with MEN1) [1][6]
- Exclude MEN1 in insulinoma: check CaPO₄, PTH, prolactin, gastrin [4]
- Pituitary macroadenoma in a young patient, especially if treatment-resistant
- Any patient with two or more MEN1-associated tumours
- Family history of any MEN1 component tumour
Triggers for MEN2 screening:
- All patients with MTC should be tested for RET mutation [2]
- Phaeochromocytoma, especially if bilateral, young onset, or familial [7]
- Family history of MTC, phaeochromocytoma, or sudden death (undiagnosed phaeo crisis)
- FHx of thyroid CA esp medullary and MEN2 [8]
- Child or infant with mucosal neuromas on lips/tongue + Marfanoid body habitus → urgent RET testing for MEN2B
- Hirschsprung disease + thyroid nodule (rare but described in MEN2A)
9.6 Differential Diagnosis of Individual Biochemical Findings
This is the biochemical signature of primary hyperparathyroidism. The DDx includes:
| Condition | PTH | Urine Ca | Other Features |
|---|---|---|---|
| Sporadic parathyroid adenoma | ↑ | ↑ | Single gland, older |
| MEN1 / MEN2A | ↑ | ↑ | Multigland, young, FHx, associated tumours |
| FHH | Normal/mildly ↑ | ↓ (Ca:Cr clearance ratio < 0.01) | CaSR mutation; benign; does NOT require surgery [3] |
| HPT-JT | ↑ | ↑ | Jaw tumours, risk of parathyroid carcinoma; CDC73 mutation |
| Lithium-induced | ↑ | Variable | History of lithium use for bipolar disorder |
| Tertiary hyperparathyroidism | ↑ | Variable | Background of chronic kidney disease |
Should perform workup for MEN: MEN1 = parathyroid hyperplasia/adenoma, pancreatic endocrine tumour, pituitary prolactinoma; MEN2A = medullary CA thyroid, pheochromocytoma, parathyroid hyperplasia [3]
| Condition | Distinguishing Feature |
|---|---|
| Sporadic phaeochromocytoma | Isolated, unilateral, older |
| MEN2 | + MTC, bilateral phaeo |
| VHL | + Haemangioblastomas, RCC |
| NF1 | + Café-au-lait, neurofibromas |
| SDHx | + H&N paragangliomas |
| Essential hypertension with anxiety | No biochemical catecholamine excess |
| Thyrotoxicosis | Weight loss, tremor, goitre, ↑T4, ↓TSH; NO elevated metanephrines |
| Drug-induced (cocaine, amphetamines) | History of substance use; transient |
| Syndrome | Gene | Inheritance | Key Tumours | Pathognomonic Feature |
|---|---|---|---|---|
| MEN1 | MEN1 (menin) | AD | PHPT, pituitary, pNET | Multigland parathyroid + gastrinoma + prolactinoma |
| MEN2A | RET | AD | MTC, phaeo, PHPT | MTC + phaeo + PHPT |
| MEN2B | RET | AD (~50% de novo) | MTC, phaeo, neuromas | Mucosal neuromas + Marfanoid habitus |
| VHL | VHL | AD | Haemangioblastoma, RCC, phaeo, pNET | Retinal/cerebellar haemangioblastoma |
| NF1 | NF1 | AD | Neurofibroma, MPNST, optic glioma, phaeo | Café-au-lait + neurofibromas + Lisch nodules |
| SDHx/PGL | SDHB/C/D | AD | Paraganglioma, GIST | H&N paraganglioma |
| Carney complex | PRKAR1A | AD | PPNAD (Cushing's), cardiac myxoma, pituitary | Cardiac myxoma + lentigines |
| HPT-JT | CDC73 | AD | PHPT, parathyroid CA, jaw fibroma | Ossifying fibroma of jaw |
| McCune-Albright | GNAS1 | Somatic mosaic | Precocious puberty, pituitary, thyroid | Polyostotic fibrous dysplasia + café-au-lait ("Coast of Maine") |
High Yield Summary
When to suspect MEN syndromes:
- Multiple endocrine tumours in one patient or family
- Young-onset endocrine tumour (PHPT < 40y, MTC < 50y, phaeo < 40y)
- Bilateral/multifocal disease (bilateral phaeo, multigland parathyroid, bilateral MTC)
- Specific triggers: ALL MTC → test RET; multiple insulinomas → test MEN1; ZES → consider MEN1 (20-30%)
Key differentiators between MEN subtypes:
- MEN1 = "3 P's" (Parathyroid + Pituitary + Pancreas); NO MTC
- MEN2A = MTC + Phaeo + PHPT; NO neuromas
- MEN2B = MTC + Phaeo + Mucosal neuromas + Marfanoid; NO PHPT
Key differential from other hereditary syndromes:
- VHL: phaeo + haemangioblastomas + RCC (NO MTC)
- NF1: phaeo + café-au-lait + neurofibromas (NO MTC)
- SDHx: H&N paragangliomas ± GIST
- FHH mimics PHPT but has LOW urine calcium — always check 24h urine Ca
- Marfan syndrome has ectopia lentis + aortic root dilatation; MEN2B does NOT
Critical rule: Always exclude phaeochromocytoma before ANY surgery in MEN2 patients.
Active Recall - Differential Diagnosis of MEN Syndromes
References
[1] Senior notes: Ryan Ho Endocrine.pdf (pages 132–133 — MEN1 and MEN2 sections) [2] Senior notes: felixlai.md (Etiology section — MEN table, RET testing for MTC) [3] Senior notes: maxim.md (Phaeochromocytoma section, Primary hyperparathyroidism section, FHH, Carney triad) [4] Senior notes: maxim.md (Insulinoma section — multiple insulinomas and MEN1 screening) [5] Senior notes: Ryan Ho Endocrine.pdf (page 38 — Medullary thyroid carcinoma) [6] Senior notes: Ryan Ho Endocrine.pdf (pages 100, 102 — Pancreatic NETs, Gastrinoma/ZES) [7] Senior notes: Ryan Ho Diagnostic Radiology.pdf (page 72 — Functional imaging, phaeochromocytoma syndromes) [8] Senior notes: Ryan Ho Fundamentals.pdf (page 426 — Thyroid lump history and risk factors) [9] Senior notes: Ryan Ho Rheumatology.pdf (page 172 — NF1 diagnostic criteria CAFESPOT) [10] Senior notes: Adrian Lui Pediatrics.pdf (pages 72, 458 — McCune-Albright syndrome, Marfan syndrome)
Diagnostic Criteria, Algorithm, and Investigations for MEN Syndromes
10. Diagnostic Criteria
MEN syndromes are diagnosed through a combination of clinical criteria and genetic confirmation. The logic is straightforward: you either have the right combination of tumours (clinical diagnosis), or you carry the causative mutation (genetic diagnosis). In practice, both are used together.
There are three routes to a MEN diagnosis:
- Clinical diagnosis (index case): a patient who develops ≥2 of the characteristic tumours for that MEN subtype
- Familial clinical diagnosis: a patient with ≥1 characteristic tumour AND a first-degree relative with a confirmed MEN diagnosis
- Genetic diagnosis: identification of a pathogenic germline mutation in MEN1 or RET, regardless of whether tumours have yet manifested (this includes presymptomatic carriers identified through cascade screening)
Why Genetic Diagnosis Matters More Than Clinical Diagnosis
The clinical criteria are useful for identifying index cases, but genetic testing is the gold standard because:
- It confirms the diagnosis definitively
- It enables presymptomatic identification of at-risk family members (cascade screening)
- In MEN2, the specific RET codon determines the timing of prophylactic thyroidectomy — clinical criteria alone cannot guide this
- ~50% of MEN2B cases are de novo (no family history), so clinical suspicion + genetic testing is the only way to catch them
MEN1 is diagnosed when any ONE of the following is met [1]:
| Criterion | Definition |
|---|---|
| Clinical | ≥2 of the 3 main MEN1 tumour types in one individual: (1) Primary hyperparathyroidism, (2) Pituitary adenoma, (3) Enteropancreatic neuroendocrine tumour |
| Familial | ≥1 MEN1-associated tumour + a first-degree relative with clinically or genetically confirmed MEN1 |
| Genetic | Identification of a pathogenic germline MEN1 mutation, even in an asymptomatic individual |
Important nuances:
- The clinical criteria require the tumours to be primary (not secondary or iatrogenic)
- Carcinoid tumours, adrenocortical tumours, angiofibromas, and collagenomas are supportive but not part of the core triad for clinical diagnosis
- Incidence: 1-18% in parathyroid adenoma, 16-38% in gastrinoma, < 3% in pituitary adenoma — so the yield of MEN1 genetic testing varies depending on the presenting tumour [1]
Who should be tested for MEN1?
- Any patient with ≥2 of the 3 main MEN1-associated tumours
- Young-onset (< 40y) primary hyperparathyroidism, especially with multigland disease
- Multiple insulinomas → consider MEN1 syndrome (sporadic insulinomas are usually solitary) [4]
- Gastrinoma (20-30% associated with MEN1) [1][6]
- Pituitary macroadenoma in young patient, especially if treatment-resistant
- Angiofibromas (64%) and collagenomas (62%) — cutaneous clues that may predate endocrine tumours [1]
- First-degree relatives of a confirmed MEN1 patient
MEN2 is diagnosed by clinical + genetic criteria [1]:
Ix and Mx: clinical + genetic diagnosis (≥1 classical features + FHx or genetics, or ≥2 features of MEN2A alone or majority of features of MEN2B alone) [1]
| Criterion | MEN2A | MEN2B |
|---|---|---|
| Clinical | ≥2 of: MTC, phaeochromocytoma, primary hyperparathyroidism | Majority of: MTC, phaeochromocytoma, mucosal neuromas, intestinal ganglioneuromas, Marfanoid habitus |
| Familial | ≥1 classical feature + first-degree relative with confirmed MEN2A or positive RET | ≥1 classical feature + confirmed RET codon 918/883 mutation |
| Genetic | Pathogenic RET gain-of-function mutation in MEN2A-associated codons | Pathogenic RET mutation in codon 918 or 883 |
Critical rule for MEN2:
- All patients with MTC should be tested for RET mutation [2][5] — this is non-negotiable because ~20% of MTC is familial, and missing MEN2 means missing the opportunity for cascade screening and prophylactic thyroidectomy in relatives
- Genetic screening: identify mutation → screen 1st degree relatives [1]
Once a RET mutation is identified, the specific codon determines the ATA risk category, which guides surveillance and timing of prophylactic thyroidectomy:
| ATA Risk | RET Codon | MEN Subtype | MTC Risk | Prophylactic Thyroidectomy |
|---|---|---|---|---|
| Highest | 918 (M918T), 883 | MEN2B | Earliest, most aggressive | Thyroidectomy during 1st year of life [1] |
| High | 634 (C634R) | MEN2A | Early childhood | Thyroidectomy at or before 5 years, guided by ↑serum calcitonin [1] |
| Moderate | 609, 611, 618, 620, 630, 804, 891 | MEN2A / FMTC | Later, variable | Thyroidectomy during childhood or young adulthood, guided by ↑serum calcitonin [1] |
11. Investigations — Systematic Approach
The investigation of MEN syndromes has two phases:
- Phase 1 — Confirm the syndrome: genetic testing + biochemical screening for all component tumours
- Phase 2 — Characterise each tumour: localisation imaging, staging, and assessment for surgical planning
Let me walk through each component systematically.
11.1 Genetic Testing (The Cornerstone)
- Gene: MEN1 at chromosome 11q13, encoding menin
- Method: Sanger sequencing or next-generation sequencing (NGS) of the entire coding region + splice sites; multiplex ligation-dependent probe amplification (MLPA) for large deletions
- Yield: ~80-90% of clinically defined MEN1 families have an identifiable MEN1 mutation; ~10-20% are mutation-negative (possible intronic/regulatory mutations or phenocopies)
- Interpretation: > 1,500 different mutations described; no genotype-phenotype correlation — you cannot predict which tumours will develop or their timing based on the specific mutation
- Cascade screening: all first-degree relatives should be offered testing once the familial mutation is identified
- Mutation-positive: enter surveillance programme
- Mutation-negative: can be discharged from surveillance (if the familial mutation is known)
- Gene: RET at chromosome 10q11.2
- Method: targeted sequencing of known hotspot exons (exons 10, 11, 13, 14, 15, 16); if negative and clinical suspicion remains high, full gene sequencing
- Yield: > 98% of clinically defined MEN2 families have an identifiable RET mutation
- Interpretation: strong genotype-phenotype correlation — the specific codon determines MEN2A vs MEN2B, aggressiveness, and management timing (see ATA table above)
- Genetic analysis for RET proto-oncogene mutation (Tyr kinase receptor) for MEN2 [5]
- Also screen asymptomatic relatives → prophylactic thyroidectomy (best done < 5-10y) [5]
Exam Pearl: MEN1 vs MEN2 Genetic Testing
- MEN1: No genotype-phenotype correlation → genetic test confirms the diagnosis but does NOT change management timing
- MEN2: Strong genotype-phenotype correlation → the specific codon directly determines the ATA risk category and the timing of prophylactic thyroidectomy. This is one of the best examples in medicine of personalised genomic medicine.
11.2 Biochemical Investigations — By Component Tumour
The principle is: once MEN is suspected or confirmed, screen for ALL component tumours, not just the presenting one. An undiagnosed phaeochromocytoma can kill a patient on the operating table; an undiagnosed gastrinoma can cause GI perforation.
| Investigation | Expected Finding | Rationale |
|---|---|---|
| Serum calcium (adjusted for albumin) | ↑ (hyperCa) | PTH-driven bone resorption + renal Ca reabsorption + intestinal absorption |
| Serum PTH | ↑ or inappropriately normal | Even a "normal" PTH in the presence of hypercalcaemia is inappropriate — it should be suppressed [3][11] |
| Serum phosphate | ↓ (hypophosphataemia) | PTH inhibits renal phosphate reabsorption via NPT2a/c downregulation in PCT |
| Vitamin D (25-OH) | Check to rule out concurrent vitamin D deficiency | Vitamin D deficiency can mask the severity of hypercalcaemia or coexist |
| 24h urine calcium | ↑ (hypercalciuria) — MUST check to rule out FHH | FHH has LOW urine Ca (Ca:Cr clearance ratio < 0.01); operating on FHH is futile [3] |
| ALP | ↑ if significant bone disease | ↑ ALP level predicts risk of hungry bone syndrome post-op [3] |
| Renal function (Cr, eGFR) | Assess for renal impairment from nephrocalcinosis | Chronic hypercalcaemia can cause tubulointerstitial nephritis |
| KUB / USG kidney | Nephrolithiasis / nephrocalcinosis | Screen for renal complications of hypercalcaemia |
| DEXA bone scan | Osteoporosis (T-score < -2.5) | Chronic PTH excess → cortical bone loss |
| Investigation | Expected Finding | Rationale |
|---|---|---|
| Serum calcitonin | ↑ | 95% of MTC produces calcitonin [2]; calcitonin is the primary tumour marker; levels correlate with tumour burden |
| Serum CEA | ↑ | 80% of MTC produces CEA [2]; rising CEA with stable/falling calcitonin suggests dedifferentiation (worse prognosis) |
| USG thyroid | Hypoechoic solid nodule(s), often bilateral; ± cervical lymphadenopathy (esp level VI) | Dx: USG thyroid, FNAC, serum calcitonin/CEA [1]; MEN2-associated MTC is typically bilateral and multifocal |
| FNAC (fine needle aspiration cytology) | MTC cells with amyloid deposits (Congo red stain); immunohistochemistry positive for calcitonin | Confirms MTC histologically; amyloid is derived from calcitonin polymerisation |
| Stimulated calcitonin test (pentagastrin or calcium stimulation) | Exaggerated calcitonin rise | Can detect C-cell hyperplasia (pre-MTC stage) in RET carriers with normal baseline calcitonin; less commonly used now with genetic testing available |
Calcitonin if Hx or clinical suspicion of familial medullary carcinoma or MEN2 [8]
Why calcitonin is such a good tumour marker for MTC:
- C cells are the ONLY significant source of calcitonin in the body
- Calcitonin has a short half-life (~10 min) so levels respond quickly to changes in tumour burden
- Post-thyroidectomy, calcitonin should become undetectable — persistent or rising levels indicate residual/recurrent disease
- Postop: serum calcitonin and CEA 6mo post-op; ↑calcitonin → screen for residual or metastatic disease [5]
This is the investigation that must be done before any surgery in MEN2 patients.
| Investigation | Expected Finding | Rationale |
|---|---|---|
| Plasma free metanephrines (metanephrine + normetanephrine) | ↑↑ | Most sensitive screening test (~99% sensitivity); metanephrines are produced continuously by COMT within the tumour, not just during catecholamine "spells" — this is why they are more sensitive than measuring catecholamines directly |
| 24h urine fractionated metanephrines | ↑↑ | 24h urine metanephrines — alternative to plasma; slightly lower sensitivity but higher specificity [3][7] |
| 24h urine catecholamines (adrenaline, noradrenaline, dopamine) | ↑ | Less sensitive than metanephrines; useful as adjunct |
| 24h urine VMA (vanillylmandelic acid) | ↑ | Terminal metabolite of catecholamines; least sensitive — largely replaced by metanephrines |
| Chromogranin A | ↑ | Non-specific neuroendocrine marker; useful for follow-up |
Why metanephrines are superior to catecholamines:
- Phaeochromocytomas express COMT (catechol-O-methyltransferase) within the tumour cells
- COMT continuously converts noradrenaline → normetanephrine and adrenaline → metanephrine within the tumour itself, independent of catecholamine secretion into the bloodstream
- Therefore metanephrine levels are continuously elevated even between paroxysms, while catecholamine levels may be normal between episodes
- This gives metanephrines their near-perfect sensitivity
Screening tests for functional adrenal tumours: ONDST + spot ARR + 24h urine metanephrines [3]
Confirmation test (if borderline results):
- Clonidine suppression test: clonidine (α₂ agonist) normally suppresses central sympathetic outflow → ↓plasma normetanephrine. In phaeochromocytoma, tumour catecholamine production is autonomous → failure to suppress [3]
| Investigation | Expected Finding | Rationale |
|---|---|---|
| Prolactin | ↑ if prolactinoma | Most common MEN1-associated pituitary tumour; prolactin > 200 μg/L virtually diagnostic of macroprolactinoma (hook effect may cause falsely normal levels in giant prolactinomas — request serial dilution) |
| IGF-1 ± GH after OGTT | ↑ IGF-1, failure of GH suppression after 75g OGTT | Screens for GH-secreting adenoma (acromegaly) |
| 24h UFC or ONDST | ↑ UFC or failure of cortisol suppression | Screens for ACTH-secreting adenoma (Cushing's disease) |
| TFT (TSH, fT4) | ↑ TSH + ↑ fT4 (inappropriate) | Screens for TSH-secreting adenoma (very rare) |
| LH, FSH, oestradiol/testosterone | Variable | Screens for gonadotroph adenoma (usually non-functioning) or hypogonadism from mass effect |
| MRI pituitary with gadolinium | Macroadenoma (85% in MEN1 vs 42% sporadic) [1]; look for suprasellar extension compressing chiasm | MRI is the imaging gold standard for pituitary; CT is inferior for soft tissue detail in the sella |
| Formal visual field testing (Goldmann/Humphrey) | Bitemporal hemianopia if chiasm compression | All patients with macroadenoma or suprasellar extension need visual field assessment |
| Investigation | Expected Finding | Rationale |
|---|---|---|
| Fasting serum gastrin | ↑ > 10× ULN + gastric pH < 2 → diagnostic of ZES [4][6] | Gastrinoma is the most common functional pNET in MEN1; PPI must be stopped before testing (PPI causes reactive hypergastrinaemia → false positive) |
| Secretin stimulation test | ↑ serum gastrin > 200 pg/mL post-secretin | Normal G cells are inhibited by secretin; gastrinoma cells are paradoxically stimulated (aberrant secretin receptors on tumour cells) [4][6] |
| Fasting glucose, insulin, C-peptide | Hypoglycaemia + ↑insulin + ↑C-peptide = insulinoma | Exclude MEN1 in insulinoma: CaPO₄, PTH, prolactin, gastrin [4] |
| Prolonged fasting test (72h fast) | Documented hypoglycaemia (BG < 3.0) with inappropriately ↑insulin and ↑C-peptide | Gold standard confirmatory test for insulinoma [4] |
| VIP | ↑ | VIPoma (Verner-Morrison syndrome) |
| Glucagon | ↑ | Glucagonoma |
| Chromogranin A (CgA) | ↑ | Non-specific but useful neuroendocrine tumour marker for follow-up [6] |
| Pancreatic polypeptide | ↑ | Non-functioning pNETs may secrete PP |
11.3 Localisation and Imaging Investigations
Once a biochemical diagnosis is established, imaging serves to localise the tumour, stage the disease, and plan surgery.
| Imaging | Technique and Key Findings | Role |
|---|---|---|
| USG neck | Parathyroid adenomas appear as hypoechoic lesions posterior to thyroid; non-invasive, readily available | First-line; but sensitivity limited for ectopic/multigland disease |
| ⁹⁹ᵐTc-Sestamibi scan | Sestamibi accumulates in mitochondria; parathyroid adenomas are rich in oxyphilic cells (lots of mitochondria) → slow washout compared to thyroid gland. Protocol: images at 10 min + 2h washout [3] | Key localisation study; combined with USG for concordance |
| SPECT (Single-photon emission CT) | 3D reconstruction with higher resolution than planar sestamibi | Better for detecting ectopic glands (mediastinal, retroesophageal) |
| 4D CT scan | Multiphase CT: arterial enhancement → washout pattern characterises parathyroid adenomas; high spatial resolution | Used when USG + sestamibi discordant or negative; high radiation dose [3] |
| Selective venous sampling | Parathyroid angiography with selective venous sampling: invasive, reserved for re-operative cases [3] | Last resort for refractory/recurrent disease |
Localisation studies of hyperfunctioning parathyroid: USG + Sestamibi scan [3]
Why sestamibi works — from first principles: Sestamibi (⁹⁹ᵐTc-MIBI) is a lipophilic cation that enters cells and accumulates in mitochondria (driven by the mitochondrial membrane potential). Parathyroid adenomas/hyperplastic glands contain abundant oxyphilic cells (oncocytes) which are packed with mitochondria. Therefore sestamibi washes out of normal thyroid tissue quickly but is retained in parathyroid tissue. On dual-phase imaging, the persistent "hot spot" at 2 hours is the parathyroid lesion. False positive: Hurthle cell adenoma (also rich in mitochondria/oxyphilic cells) [3].
Special consideration in MEN:
- MEN1 and MEN2A typically have multigland hyperplasia (all 4 glands affected), not a single adenoma
- Sestamibi sensitivity is lower for multigland disease than for single adenomas (~50-60% vs ~80-90%)
- This is why bilateral neck exploration (BCE) is preferred in MEN1/2A, rather than focused/minimally invasive parathyroidectomy [3]
| Imaging | Key Findings | Role |
|---|---|---|
| USG thyroid | Hypoechoic solid nodule(s), bilateral/multifocal; microcalcifications; ± suspicious cervical LNs (loss of hilum, round shape, microcalcification, intranodal cystic necrosis) | First-line; guides FNAC; assesses nodal involvement [1][8] |
| FNAC with calcitonin washout | MTC cells + amyloid on cytology; calcitonin immunocytochemistry positive; calcitonin measured in FNAC washout fluid (very sensitive for confirming MTC in suspicious nodes) | Diagnostic confirmation |
| CT neck/chest/abdomen with contrast | Staging: local invasion, nodal disease, distant metastases (lungs, liver, bone) | Pre-operative staging for known MTC |
| 68Ga-DOTATATE PET-CT | Somatostatin receptor-positive: well-differentiated MTC shows uptake | Somatostatin-receptor-based imaging for staging and detecting metastases [6] |
| 18F-DOPA PET-CT | High sensitivity for MTC (MTC cells take up and decarboxylate DOPA as part of APUD/neuroendocrine metabolism) | Increasingly used for MTC staging; superior sensitivity to conventional CT for small metastases |
| Imaging | Key Findings | Role |
|---|---|---|
| CT adrenals (with contrast) | Phaeochromocytoma: typically > 3cm, heterogeneous, high attenuation on non-contrast CT ( > 10 HU) (lipid-poor, unlike benign adenomas which are lipid-rich < 10 HU); may show areas of necrosis/haemorrhage; bilateral in MEN2 | First-line imaging; CT/MRI more accurate in primary tumours [7] |
| MRI adrenals | "Light bulb" sign: markedly hyperintense on T2W (due to high water content from cystic/necrotic areas and rich vascularity); does not lose signal on out-of-phase (no intracellular lipid unlike adenoma) | Preferred in young patients/pregnancy (no radiation); excellent soft tissue characterisation |
| ¹²³I or ¹³¹I-MIBG scan | MIBG (metaiodobenzylguanidine) is a noradrenaline analogue taken up by the noradrenaline transporter (NET) into chromaffin cells; 85% sensitivity, 95% specificity [7] | Less sensitive for primary tumours than CT/MRI but more sensitive for extra-adrenal tumours and metastatic disease [7] |
| 68Ga-DOTATATE PET-CT | High sensitivity for detecting metastatic/extra-adrenal disease via somatostatin receptor expression | Increasingly first-line for staging; superior to MIBG for SDHB-related tumours |
| 18F-FDG PET-CT | Increased glucose metabolism in malignant/aggressive phaeo | Useful for suspected malignant phaeochromocytoma |
| 18F-DOPA PET-CT or 18F-FDA PET-CT | Catecholamine synthesis pathway tracers | PET/CT tracers: 18F-FDA, 18F-DOPA, 11C-epinephrine, 18FDG, 68Ga dotatate [7] |
Why MIBG works — from first principles: MIBG (meta-iodobenzylguanidine) is structurally similar to noradrenaline. It is taken up by the noradrenaline transporter (NET / uptake-1) on the surface of chromaffin cells and stored in catecholamine storage vesicles. Since phaeochromocytomas are derived from chromaffin cells, they avidly take up and retain MIBG, producing a "hot spot" on scintigraphy. Labelling with ¹²³I (for diagnostic imaging) or ¹³¹I (for therapy) enables both diagnosis and targeted radionuclide therapy.
| Imaging | Key Findings | Role |
|---|---|---|
| Contrast CT/MRI pancreas | Highly vascular (early arterial enhancement with portal venous washout) with T1W-hypointense and T2W-hyperintense [6] | First-line; sensitivity 60–70% for small tumours [4] |
| EUS (endoscopic ultrasound) | Detects lesions as small as 2-3mm in diameter [6]; can perform FNA for tissue diagnosis | Highest pre-operative sensitivity for small pancreatic NETs |
| 68Ga-DOTATATE PET-CT | Somatostatin receptor-avid uptake in well-differentiated NETs | Somatostatin-receptor-based imaging; less useful for poorly differentiated NETs with low sstr expression [6] |
| Arterial stimulation with hepatic venous sampling (ASVS) | Inject 10% Ca gluconate at 4 different arteries (GDA, SMA, splenic a., hepatic a.); sample R hepatic vein for 30s & 60s; 2-fold increase in insulin localises to that arterial territory [4] | Reserved for insulinomas not localised by cross-sectional imaging |
| Intraoperative ultrasound (IOUS) | Gold standard for localisation [4]; direct visualisation of tumour relationship to pancreatic duct | Essential during surgery to guide extent of resection |
| Imaging | Key Findings | Role |
|---|---|---|
| MRI pituitary with gadolinium | Microadenoma: hypointense focus in pituitary that enhances less than normal pituitary on early post-contrast images; Macroadenoma: > 10mm, may extend suprasellarly into optic chiasm or laterally into cavernous sinus | Gold standard for pituitary imaging; 85% macroadenoma in MEN1 [1] |
12. Surveillance Protocols for Confirmed MEN Carriers
Once a genetic diagnosis is confirmed, lifelong biochemical and imaging surveillance is required. The schedules differ by syndrome.
| Component | Screening Test | Frequency | Start Age |
|---|---|---|---|
| Hyperparathyroidism | Serum Ca, PTH, albumin | Annually | 8 years |
| Pituitary adenoma | Prolactin, IGF-1 + MRI pituitary | Annually (biochemistry); MRI every 3 years | 5 years |
| Enteropancreatic NET | Fasting gastrin, fasting glucose, insulin, chromogranin A + CT/MRI or EUS | Annually (biochemistry); imaging every 1-3 years | 8 years |
| Carcinoid (thymic/bronchial) | CT chest | Every 1-2 years | 15 years |
| Adrenocortical tumour | CT abdomen (when doing pancreatic imaging) | Every 1-3 years | 10 years |
Monitoring and screening [1]:
| Component | Screening Test | Frequency | Start Age |
|---|---|---|---|
| MTC | Serum calcitonin ± CEA | Annually; guides timing of prophylactic thyroidectomy | Highest risk (MEN2B): from birth; High risk: from age 3-5; Moderate risk: from age 5 |
| Phaeochromocytoma | Annual screening by plasma/urine metanephrines | Annually | From 11y or 16y depending on risk [1] |
| Hyperparathyroidism (MEN2A only) | Annual screening by serum Ca ± PTH | Annually | From 11y or 16y depending on risk (or NOT needed if MEN2B) [1] |
Surveillance Timing by ATA Risk
| ATA Risk | Phaeo Screening Start | PHPT Screening Start | Thyroidectomy |
|---|---|---|---|
| Highest (codon 918) | 11 years | Not needed (MEN2B) | Within 1st year of life |
| High (codon 634) | 11 years | 11 years | By age 5 |
| Moderate (other codons) | 16 years | 16 years | Guided by calcitonin |
14. Interpretation Pitfalls and Special Considerations
| Scenario | Pitfall | Solution |
|---|---|---|
| "Normal" PTH with hypercalcaemia | Even if PTH is within reference range, a hyperCa of non-parathyroid cause should have appropriately suppressed PTH → workup for 1° hyperparathyroidism should ensue [11] | Always interpret PTH in context of calcium level |
| Gastrin elevation on PPI | PPI-induced achlorhydria → reactive hypergastrinaemia (feedback: low acid → ↑gastrin from normal G cells) → false positive | PPI should be stopped before evaluation for ZES [6] |
| Giant prolactinoma with "normal" prolactin | Hook effect: very high prolactin saturates both capture and detection antibodies → falsely normal result | Request serial dilution of the sample |
| Phaeochromocytoma with "normal" catecholamines | Catecholamines are secreted episodically; metanephrines are produced continuously within the tumour | Always use plasma free metanephrines or 24h urine fractionated metanephrines, NOT spot catecholamines |
| Sestamibi scan negative in MEN | Multigland hyperplasia has lower sestamibi sensitivity (~50-60%) than single adenoma (~80-90%) | In MEN, favour bilateral neck exploration regardless of imaging; false positive: Hurthle cell adenoma [3] |
This is a critical operational principle:
Step 1: Screen for phaeochromocytoma (plasma metanephrines) Step 2: If phaeo present → treat phaeo FIRST (alpha blockade → surgery) Step 3: THEN proceed to thyroidectomy for MTC Step 4: THEN address hyperparathyroidism if present
Why this order? An undiagnosed phaeochromocytoma under general anaesthesia for thyroidectomy can cause a catecholamine crisis (massive surge of adrenaline/noradrenaline → hypertensive emergency → arrhythmias → cardiac arrest → death). This is why screening for phaeo is the FIRST investigation in any MEN2 patient being considered for surgery.
Critical Safety Rule
In MEN2, ALWAYS screen for and exclude phaeochromocytoma BEFORE thyroidectomy or any other surgery. The sequence is: phaeo screen → phaeo treatment (if present) → thyroidectomy → parathyroid management. Violating this order can be fatal.
High Yield Summary
Diagnostic Criteria:
- MEN1: ≥2 of 3 core tumours (PHPT, pituitary, pNET) OR ≥1 tumour + affected 1st-degree relative OR pathogenic MEN1 mutation
- MEN2: ≥2 classical features OR ≥1 feature + FHx/genetics OR RET mutation alone
Genetic Testing:
- MEN1: MEN1 gene sequencing (no genotype-phenotype correlation; > 1500 mutations described)
- MEN2: RET proto-oncogene targeted exon sequencing (strong genotype-phenotype correlation; specific codon guides management)
- ALL MTC patients must be tested for RET regardless of family history
Key Biochemical Investigations:
- PHPT: hyperCa + ↑/normal PTH + ↑urine Ca (must exclude FHH)
- MTC: serum calcitonin (95%) + CEA (80%)
- Phaeo: plasma free metanephrines (most sensitive) or 24h urine fractionated metanephrines
- pNETs: fasting gastrin (ZES), fasting glucose/insulin/C-peptide (insulinoma), chromogranin A
- Pituitary: prolactin, IGF-1, cortisol, TFT, gonadotropins + MRI pituitary
Key Imaging:
- Parathyroid: USG + Sestamibi scan (sestamibi accumulates in mitochondria-rich oxyphilic cells)
- MTC: USG thyroid + FNAC + CT staging
- Phaeo: CT/MRI adrenals (first-line) + MIBG scan (85% sens, 95% spec) or 68Ga-DOTATATE PET-CT
- pNETs: contrast CT/MRI + EUS (detects lesions as small as 2-3mm) + 68Ga-DOTATATE PET-CT
Critical Operational Rule: In MEN2, screen for phaeo FIRST → treat phaeo → then thyroidectomy → then parathyroid.
Active Recall - Diagnostic Criteria, Algorithm, and Investigations
References
[1] Senior notes: Ryan Ho Endocrine.pdf (pages 132–133 — MEN1 and MEN2 clinical presentation, surveillance, and diagnostic criteria) [2] Senior notes: felixlai.md (Diagnosis section — calcitonin, CEA, RET testing for MTC) [3] Senior notes: maxim.md (Primary hyperparathyroidism — biochemical diagnosis, sestamibi, FHH; Adrenal incidentaloma — screening tests; Phaeochromocytoma — clonidine suppression test; Bilateral neck exploration in MEN) [4] Senior notes: maxim.md (Insulinoma — MEN1 screening tests, prolonged fasting test, ASVS; Gastrinoma — fasting gastrin, secretin test) [5] Senior notes: Ryan Ho Endocrine.pdf (page 38 — MTC diagnosis, RET testing, prophylactic thyroidectomy, calcitonin/CEA follow-up) [6] Senior notes: Ryan Ho Endocrine.pdf (pages 100, 102 — Pancreatic NETs approach, gastrinoma diagnosis, somatostatin receptor imaging, chromogranin A) [7] Senior notes: Ryan Ho Diagnostic Radiology.pdf (page 72 — Functional imaging for adrenal tumours, MIBG, PET/CT tracers) [8] Senior notes: Ryan Ho Fundamentals.pdf (page 427 — Thyroid workup, calcitonin for familial MTC/MEN2, USG findings) [11] Senior notes: Ryan Ho Chemical Path.pdf (page 23 — Hypercalcaemia workup, PTH interpretation, MEN screening)
Management of MEN Syndromes
Managing MEN syndromes is fundamentally different from managing sporadic endocrine tumours. Here's why:
- Multiple tumours develop sequentially over a lifetime — you're not curing one disease, you're managing a lifelong genetic predisposition
- The order of treatment matters — treating the wrong tumour first can be fatal (e.g. thyroidectomy before addressing phaeochromocytoma)
- Multifocality changes the surgical strategy — you can't just excise one gland and declare victory; recurrence is the rule, not the exception
- Prophylactic surgery is part of the armamentarium — particularly thyroidectomy in MEN2
- Lifelong surveillance is mandatory — new tumours can develop at any time
- Genetic cascade screening saves lives in the family — identifying at-risk relatives and intervening before tumours develop
The management of each MEN component follows the principle: screen → biochemically confirm → localise → treat (in the correct order) → lifelong follow-up.
The cardinal rule in MEN2 is the treatment priority sequence. In MEN1, there is more flexibility, but the general approach is to address the most life-threatening or symptomatic component first.
Treatment Priority in MEN2
The sequence is absolute and non-negotiable:
- Phaeochromocytoma FIRST (alpha-blockade → surgery) — because undiagnosed phaeo under GA = catecholamine crisis = death
- Medullary thyroid carcinoma SECOND (total thyroidectomy + central LN dissection)
- Hyperparathyroidism THIRD (only if symptomatic, and only in MEN2A)
Violating this order can be fatal.
17. Management of Each Component
17.1 Phaeochromocytoma (MEN2A and MEN2B)
An undiagnosed or untreated phaeochromocytoma during anaesthesia can cause a massive catecholamine surge → hypertensive crisis (systolic BP > 250 mmHg), malignant arrhythmias (VT, VF), acute pulmonary oedema, intracranial haemorrhage, or cardiovascular collapse. The surgical manipulation itself, intubation, and anaesthetic agents can all trigger catecholamine release. This is why phaeochromocytoma is always addressed before any other surgery.
Medical therapy: pre-operative prevention of crisis by combined α/β-blockade [1]
| Step | Drug | Mechanism | Duration | Key Points |
|---|---|---|---|---|
| Step 1: α-blockade | Phenoxybenzamine (irreversible, non-selective α-blocker) | Blocks α₁ receptors on vascular smooth muscle → ↓peripheral vascular resistance → ↓BP; also blocks α₂ presynaptic receptors → ↑NA release (reflex tachycardia) | At least 7-14 days before surgery [1] | Adequate α-blockade indicated by postural BP drop [1]; start 10mg BD, titrate up; target seated BP < 130/80 with no orthostatic hypotension below 80/45 |
| Step 2: β-blockade | Propranolol (or atenolol, metoprolol) | Blocks β₁ → ↓HR, ↓contractility; controls reflex tachycardia from α-blockade | Added 2-3 days AFTER adequate α-blockade | β-blockade alone will cause unopposed α-adrenergic activity → exacerbate HTN [1]; ALWAYS α before β |
| Step 3: Volume expansion | High-sodium diet ( > 5g/day) + liberal fluids | ↑Na diet and fluid intake to reverse catecholamine-induced intravascular volume contraction (to prevent postop hypotension) [1] | Throughout pre-op period | Chronic catecholamine excess causes vasoconstriction → ↓intravascular volume; once tumour is removed, sudden loss of catecholamine drive → vasodilation → hypotension unless volume is pre-expanded |
Alternative α-blockers:
- Doxazosin (selective α₁-blocker): fewer side effects than phenoxybenzamine, easier to titrate, but reversible (shorter duration of action)
- Dipine CCBs (e.g. nifedipine, amlodipine): useful adjunct; direct vasodilator, no postural hypotension [1]
- Metyrosine (α-methylparatyrosine): inhibits catecholamine synthesis at the tyrosine hydroxylase step; used in combination with α-blockade for difficult-to-control cases [1]
Why Alpha Before Beta — From First Principles
If you give a β-blocker alone to a patient with phaeochromocytoma:
- β₂ receptors on skeletal muscle arterioles normally cause vasodilation (when stimulated by adrenaline)
- Blocking β₂ removes this vasodilatory counterbalance
- α₁ receptors on vascular smooth muscle remain fully active and unopposed
- Result: unopposed α₁-mediated vasoconstriction → catastrophic hypertensive crisis
This is why ALWAYS initiate α-blockade before β-blockade [1].
Mx: similar to sporadic cases with alpha blockade followed by adrenalectomy (unilateral suffice) [1]
| Aspect | Details |
|---|---|
| Approach | Laparoscopic, robotic with retroperitoneal or transabdominal approach [1]; laparoscopic preferred for tumours < 6cm [3] |
| Extent | Unilateral adrenalectomy for unilateral phaeo; bilateral adrenalectomy if bilateral (common in MEN2, 30-100%) |
| Cortical-sparing adrenalectomy | Increasingly favoured in MEN2 when bilateral phaeo → preserves adrenal cortex to avoid lifelong steroid replacement; removes medulla (where the phaeo arises) while leaving cortical rim; risk of recurrence (~10-15%) but avoids Addisonian crisis |
| Open adrenalectomy | Reserved for tumours > 6cm or suspected malignancy [3] |
Why cortical-sparing matters in MEN2:
- In MEN2, phaeo is bilateral in 30-100% of cases → bilateral total adrenalectomy would leave the patient with permanent adrenal insufficiency (requiring lifelong glucocorticoid AND mineralocorticoid replacement)
- Addisonian crisis (acute adrenal insufficiency: hypotension, hypoglycaemia, hyperkalaemia, shock) can be life-threatening if the patient forgets to take steroids or becomes unwell
- Cortical-sparing surgery preserves enough cortex to maintain basal steroid production, avoiding this lifelong dependency
Postop complications: HTN crisis, hypotension, rebound hypoglycaemia → monitor BP, HR, H'stix closely postop [1]
| Complication | Mechanism | Management |
|---|---|---|
| Hypotension | Sudden loss of catecholamine drive → vasodilation + depleted intravascular volume | IV fluid resuscitation; pre-op volume expansion minimises this |
| Rebound hypoglycaemia | Catecholamines normally suppress insulin and promote glycogenolysis; sudden loss of catecholamines → unopposed insulin action | Monitor H'stix Q1-2h for 24h post-op; IV dextrose if needed |
| Persistent HTN | Incomplete resection, metastatic disease, or volume overload | Re-evaluate with biochemistry and imaging |
| Adrenal insufficiency (if bilateral total adrenalectomy) | Loss of cortisol and aldosterone production | Lifelong hydrocortisone + fludrocortisone replacement |
Management of phaeochromocytoma crisis: classified as hypertensive urgency [1]
- ICU monitoring
- IV phentolamine (short-acting α-blocker): bolus 2-5mg IV, repeat as needed; or IV infusion
- Nitroprusside infusion: if phentolamine insufficient
- β-blocker (e.g. esmolol IV): ONLY after adequate α-blockade
- Magnesium sulphate IV: direct vasodilator + antiarrhythmic
- Emergency surgery if refractory
17.2 Medullary Thyroid Carcinoma (MEN2A and MEN2B)
This is one of the most important and unique aspects of MEN2 management. Because virtually all MEN2 patients develop clinically apparent MTC [2], prophylactic removal of the thyroid before MTC develops (or while it's still at the C-cell hyperplasia stage) is potentially curative.
Monitor calcitonin with prophylactic thyroidectomy depending on risk of mutation and calcitonin level [1]:
| ATA Risk | Timing | Rationale |
|---|---|---|
| Highest (MEN2B: codon 918/883) | Thyroidectomy during 1st year of life [1] | MTC can develop in infancy; delay means metastatic disease |
| High (MEN2A: codon 634) | Thyroidectomy at or before 5 years, guided by ↑serum calcitonin [1] | MTC typically develops in childhood; early thyroidectomy prevents clinically significant disease |
| Moderate (other codons) | Thyroidectomy during childhood or young adulthood, guided by ↑serum calcitonin [1] | MTC onset is later and more variable; annual calcitonin monitoring can guide timing; some advocate delaying until calcitonin rises above baseline |
Mx: total thyroidectomy + central LN dissection [1]
| Procedure | Details | Rationale |
|---|---|---|
| Total thyroidectomy | Removal of entire thyroid gland including both lobes and isthmus | MTC in MEN2 is bilateral and multifocal — hemithyroidectomy is insufficient [1][5] |
| Central lymph node dissection (level VI) | Routine central ± neck dissection (depending on calcitonin level and imaging evidence of nodal mets) [5] | MTC metastasises early via lymphatics; level VI (central compartment) is the first echelon of nodal spread |
| Lateral neck dissection | Selective lateral neck dissection (levels II-V) if imaging or calcitonin suggests lateral nodal disease | Calcitonin > 200 pg/mL or positive lateral nodes on imaging |
Postop: no need suppressive doses of T4 (not TSH-responsive), serum calcitonin/CEA screening [1]
| Aspect | Details | Rationale |
|---|---|---|
| Thyroid hormone replacement | Levothyroxine to maintain euthyroid (normal TSH) | Unlike differentiated thyroid cancer (papillary/follicular), MTC arises from C cells which do NOT express TSH receptors → TSH suppression is pointless and harmful (causes iatrogenic thyrotoxicosis) [5] |
| Calcitonin and CEA monitoring | Serum calcitonin and CEA 6mo post-op [5]; then 6-12 monthly | Calcitonin is the most sensitive marker for residual/recurrent MTC; ↑calcitonin → screen for residual or metastatic disease → surgical Tx ± chemo/RT [5] |
| Interpretation of post-op calcitonin | Undetectable = biochemical cure; detectable but stable = watch; rising = recurrence/metastasis | Calcitonin doubling time < 6 months = aggressive; > 2 years = indolent |
| Imaging for recurrence | USG neck, CT neck/chest/abdomen, 68Ga-DOTATATE PET-CT or 18F-DOPA PET-CT | If calcitonin rising, localise the recurrence for possible surgical salvage |
No good adjuvant Tx for MTC [5] — it does not respond to radioactive iodine (MTC cells don't express NIS/thyroglobulin), and conventional chemotherapy has limited efficacy. However:
| Treatment | Indication | Mechanism |
|---|---|---|
| Vandetanib | Locally advanced or metastatic MTC | Multi-kinase inhibitor targeting RET, VEGFR, EGFR → "vandetanib" = "VAN-det-a-nib" — inhibits the very RET kinase that drives MEN2 |
| Cabozantinib | Progressive metastatic MTC | Multi-kinase inhibitor targeting RET, MET, VEGFR2 |
| Selpercatinib / Pralsetinib | RET-mutant advanced MTC (2020+ approvals) | Highly selective RET inhibitors — represent a breakthrough in MEN2-associated MTC; directly target the constitutively active RET kinase; better response rates and tolerability than non-selective TKIs |
| External beam radiotherapy | Locally advanced, unresectable disease; palliative | Limited role; MTC is relatively radioresistant |
| Systemic chemotherapy | Refractory disease | Dacarbazine-based regimens; poor response rates |
Selpercatinib — The RET Revolution
Selpercatinib (LOXO-292, brand name Retevmo) is a highly selective RET kinase inhibitor approved in 2020 for RET-mutant MTC. This is a perfect example of precision medicine — the drug directly targets the exact molecular defect (constitutively active RET) that causes MEN2. In the LIBRETTO-001 trial, selpercatinib achieved an overall response rate of ~73% in treatment-naïve RET-mutant MTC. This is now considered first-line for advanced/metastatic RET-mutant MTC.
17.3 Primary Hyperparathyroidism
The surgical approach to hyperparathyroidism in MEN differs fundamentally from sporadic disease because the pathology is multigland hyperplasia (all 4 glands affected) rather than a single adenoma.
Management: indication of surgery same as sporadic; favours subtotal PTHectomy (3.5 glands) + cervical thymectomy (↓thymic carcinoid) [1]
Indications for surgery (same as sporadic PHPT) [1][3][12]:
- ALL symptomatic patients (renal stones, bone disease, neuromuscular symptoms) [12]
- Asymptomatic patients meeting criteria (mnemonic: CASR) [3]:
- Ca: adjusted Ca ≥ 2.8 mmol/L (i.e. > 0.25 mmol/L above ULN)
- Age < 50
- Skeletal: DEXA T-score < -2.5 or vertebral fracture
- Renal: CrCl < 60 mL/min, or 24h urine Ca > 10 mmol/L, or nephrolithiasis/nephrocalcinosis on imaging
Surgical approach — why NOT focused parathyroidectomy in MEN:
| Approach | When to Use | Technique |
|---|---|---|
| Focused parathyroidectomy | Indication: adenoma identified on pre-op localization [3] — this is for SPORADIC PHPT (single adenoma premise, 80% of cases) | Small incision, pre-op localisation, intra-op PTH assay (Miami criteria: PTH drop to normal range + < 50% of max value at 10min post-resection) [3] |
| Bilateral neck exploration (BCE) | Indications: MEN1/2A, uncertain imaging, conversion from focused parathyroidectomy [3] | Kocher's incision |
In MEN, focused parathyroidectomy is inappropriate because:
- The disease is multigland hyperplasia — removing one gland leaves 3 hyperplastic glands behind → guaranteed recurrence
- Sestamibi is less sensitive for multigland disease → may miss affected glands
MEN1 surgical options:
| Procedure | Technique | Pros | Cons |
|---|---|---|---|
| Subtotal parathyroidectomy ("3.5 glands") | 3 glands resected; fourth gland: ½ gland taken out for frozen section (to confirm parathyroid tissue), remaining ½ gland left in situ, marked with non-absorbable sutures [3] | Avoids permanent hypoparathyroidism; marked remnant aids re-operation if recurrence | High recurrence rate ( > 50% in 12 years if subtotal) [1] |
| Total parathyroidectomy with autotransplantation | All 4 glands removed; small fragments autotransplanted to forearm (brachioradialis) or neck (SCM) | Easier to access transplanted tissue if recurrence; lower recurrence rate | Risk of permanent hypoparathyroidism if graft fails; requires cryopreservation of tissue as backup |
| ± Cervical thymectomy | Indicated if MEN1 to resect supernumerary glands in thymus [3] and ↓thymic carcinoid [1] | Removes ectopic/supernumerary parathyroid tissue; reduces risk of thymic carcinoid (a known MEN1 complication) | Additional surgical morbidity |
Why "3.5 glands" in MEN? The reasoning is pragmatic: you want to remove as much hyperplastic tissue as possible to control hypercalcaemia, while leaving enough parathyroid tissue to prevent permanent hypoparathyroidism (which requires lifelong calcium + vitamin D supplementation and carries risks of hypocalcaemic seizures, arrhythmias, and cataracts). The frozen section of the excised half-gland confirms you are indeed leaving parathyroid tissue behind (not a lymph node or fat) [3].
Post-operative complications specific to parathyroidectomy in MEN [3]:
| Complication | Mechanism | Management |
|---|---|---|
| Hungry bone syndrome | Rapid, profound hypocalcaemia due to sudden drop in PTH → rapid deposition of Ca into demineralised bone [3] | Predicted by ↑ALP pre-op [3]; IV calcium gluconate + high-dose oral calcium + calcitriol |
| Transient hypocalcaemia | Suppressed remaining gland(s) or remnant takes time to recover | Calcium and vitamin D supplementation; usually resolves in days-weeks |
| Permanent hypoparathyroidism | Insufficient remnant tissue or devascularised remnant; requiring Ca/vit D supplement 1 year post-op [3] | Lifelong calcium + calcitriol replacement |
| Recurrence | New hyperplasia in remnant or autograft; > 50% in 12 years [1] | Re-operation guided by sestamibi/4D-CT localisation |
| RLN injury | Intraoperative damage to recurrent laryngeal nerve | Bilateral RLN injury can be life-threatening [12] → stridor, need for tracheostomy |
Mx: similar to MEN1, NOT for prophylactic parathyroidectomy during thyroidectomy (usually asymptomatic) [1]
Key differences from MEN1:
- Usually mild and asymptomatic → most patients do NOT require surgery
- If symptomatic or meeting surgical criteria, same approach as MEN1 (subtotal parathyroidectomy)
- During thyroidectomy for MTC, the surgeon should inspect but NOT routinely remove normal-appearing parathyroid glands — removing asymptomatic normal glands causes unnecessary hypoparathyroidism
- If inadvertently devascularised during thyroidectomy → autotransplant into the forearm or SCM
Management: same as sporadic adenomas [1]
| Tumour Type | First-Line Treatment | Second-Line | Rationale |
|---|---|---|---|
| Prolactinoma | Dopamine agonist (cabergoline > bromocriptine) | Transsphenoidal surgery if DA-resistant or intolerant | Prolactinomas express D₂ receptors; DA agonists shrink tumour + normalise prolactin in ~80-90%; surgery rarely needed |
| GH-secreting (acromegaly) | Transsphenoidal surgery | Somatostatin analogues (octreotide, lanreotide), pegvisomant, RT | Surgery is first-line because DA agonists are much less effective for GH tumours |
| ACTH-secreting (Cushing's) | Transsphenoidal surgery | Medical (metyrapone, ketoconazole, pasireotide), bilateral adrenalectomy, pituitary RT | Surgery aims for biochemical cure (undetectable post-op cortisol) |
| Non-functioning | Transsphenoidal surgery (if mass effect) | Surveillance if small and no mass effect | No hormonal target for medical therapy |
Special considerations in MEN1:
- 85% are macroadenomas (larger at diagnosis than sporadic) [1] → more likely to cause mass effect and be treatment-resistant
- Recurrence is more common → need closer MRI follow-up (every 1-3 years lifelong)
- Lactotroph (prolactin-secreting) tumours are most common (20%) [1] — but you MUST screen for co-secretion (GH + prolactin is possible in mammosomatotroph adenomas)
17.5 Enteropancreatic Neuroendocrine Tumours (MEN1)
The management of pNETs in MEN1 is fundamentally different from sporadic pNETs because of multifocality — there are often dozens of small tumours throughout the pancreas and duodenum. This means surgical cure is very difficult, and the approach must balance tumour control against the morbidity of extensive pancreatic surgery.
Mx: generally prefer medical treatment by high-dose PPI due to multifocality → low cure rate by OT [1]
| Treatment | Indication | Details |
|---|---|---|
| High-dose PPI | All MEN1-associated gastrinoma [1][4][6] | Controls acid hypersecretion and heals ulcers; e.g. omeprazole 40-60mg BD; does NOT address the tumour itself but prevents the clinical consequences |
| Surgical resection | Sporadic gastrinoma (non-metastatic) [4]; in MEN1, surgery is considered only if a dominant/large tumour ( > 2cm) is identified | Pancreatic gastrinomas: enucleation + peripancreatic LN dissection; Duodenal gastrinomas: enucleation if small, full-thickness excision if large [4] |
| Octreotide (somatostatin analogue) | Adjunct; metastatic disease | Binds somatostatin receptors on tumour cells → ↓gastrin secretion; also antiproliferative |
| Systemic chemotherapy | Metastatic disease | Streptozocin/5-FU, temozolomide/capecitabine, everolimus, sunitinib |
| Liver-directed therapy | Hepatic metastases | Hepatic resection (curative), hepatic artery embolisation (palliative) [6] |
Why medical over surgical for MEN1-associated gastrinoma?
- MEN1 gastrinomas are multifocal (dozens of microadenomas in the duodenal wall and pancreas) [1][6]
- 50-88% sporadic and 70-100% MEN1-associated gastrinomas are in the duodenum [6] — scattered along the wall
- Surgical cure rate is very low (~0-10%) because you simply cannot remove them all without destroying the entire duodenum and pancreas
- PPI effectively controls the clinical consequences (ulcers, diarrhoea) even though the tumour persists
- Surgery is reserved for large ( > 2cm), dominant tumours to prevent or treat metastatic spread
Surgical treatment: advised for ALL patients [4]
Unlike gastrinoma, insulinoma in MEN1 is usually a dominant single tumour (even if multiple are present) causing the hypoglycaemia, and surgical cure is achievable.
| Treatment | Details |
|---|---|
| Medical (bridging) | Diazoxide: ↓insulin release (opens K-ATP channels on β-cells → inhibits insulin secretion); S/E: oedema, hirsutism [4]. Octreotide (2nd line): inhibits insulin secretion via sst₂/sst₅ receptors [4] |
| Surgery | Open surgery with extended Kocher manoeuvre and mobilisation of entire pancreas → IOUS to locate tumour and identify relation to duct → determine surgical extent [4] |
| Enucleation | For superficial tumours not involving the pancreatic duct [4] |
| Distal pancreatectomy | For tumours deep in body/tail of pancreas or ductal involvement [4] |
| Whipple's operation | For tumours deep in head/neck of pancreas [4] |
| Alternative | EUS-guided alcohol ablation [4] |
| Inoperable/metastatic | Chemotherapy: doxorubicin, everolimus [4]; PRRT (¹⁷⁷Lu-DOTATATE) |
Management: in general resect if > 1-2cm or functional, otherwise observe [6]
- In MEN1, many non-functioning pNETs are < 1cm and indolent → surveillance with annual imaging
- Surgery (distal pancreatectomy or enucleation) is considered for tumours > 2cm or with evidence of growth (risk of lymph node metastasis increases significantly above 2cm)
- Debulking surgery for metastatic disease to improve quality of life and enable medical therapy
- These are rare even in MEN1
- Principles: symptom control (octreotide) + surgical resection if resectable
- Metastatic: targeted therapy (everolimus, sunitinib), PRRT (¹⁷⁷Lu-DOTATATE), chemotherapy
| Type | Clinical Significance | Management |
|---|---|---|
| Thymic carcinoid | Aggressive; predominantly in male smokers; poor prognosis even after resection | Surgical resection if feasible; cervical thymectomy during parathyroidectomy is recommended in MEN1 to reduce risk [1][3] |
| Bronchial carcinoid | Usually indolent; rarely causes carcinoid syndrome | Surgical resection if symptomatic or growing; surveillance for small, stable lesions |
| Gastric carcinoid (Type 2) | Associated with hypergastrinaemia (from gastrinoma-driven chronic acid suppression or direct gastrin-trophic effect on ECL cells) | Endoscopic resection for small ( < 2cm), localised lesions; surgery for larger/invasive tumours |
| Component | MEN1 Mx | MEN2A Mx | MEN2B Mx |
|---|---|---|---|
| PHPT | Subtotal PTHectomy (3.5 glands) + cervical thymectomy; indication same as sporadic | If symptomatic: same as MEN1; NOT prophylactic PTHectomy during thyroidectomy [1] | Not applicable (no PHPT in MEN2B) |
| Pituitary | Same as sporadic (DA agonist for prolactinoma, TSS for others) | Not applicable | Not applicable |
| Pancreatic NETs | Gastrinoma: high-dose PPI (medical preferred); Insulinoma: surgery | Not applicable | Not applicable |
| MTC | Not applicable | Total thyroidectomy + central LN dissection [1]; prophylactic by ATA risk | Thyroidectomy within 1st year of life [1]; total thyroidectomy + central LN dissection if established MTC |
| Phaeo | Not applicable | Alpha blockade → beta blockade → adrenalectomy [1]; cortical-sparing if bilateral | Same as MEN2A |
| Mucosal neuromas | Not applicable | Not applicable | Symptomatic management only; not resectable |
| Ganglioneuromas | Not applicable | Not applicable | Symptomatic (laxatives for constipation); surgery for obstruction/megacolon |
This is not a separate "treatment" but is an integral part of MEN management.
Genetic screening: identify mutation → screen 1st degree relatives [1]
| Aspect | Details |
|---|---|
| Who to test | ALL first-degree relatives (parents, siblings, children) of a confirmed MEN mutation carrier |
| When to test | As early as possible; in MEN2B, within the first weeks of life (to enable prophylactic thyroidectomy in the first year); in MEN2A, by age 3-5; in MEN1, by age 5-10 |
| How | Targeted sequencing of the known familial mutation (much simpler than full gene sequencing) |
| If positive | Enter lifelong surveillance programme + consider prophylactic surgery (MEN2) |
| If negative | Can be discharged from surveillance (if the familial mutation is known and confirmed absent) — this provides enormous psychological relief |
| Counselling | Pre-test and post-test genetic counselling is mandatory; discuss implications for reproductive planning, insurance, psychological impact; 50% chance of transmission to each offspring |
19. Contraindications and Special Situations
| Situation | Explanation |
|---|---|
| Familial hypocalciuric hypercalcaemia (FHH) | Surgical intervention does not result in cure [12] — the CaSR mutation means hypercalcaemia persists regardless of how many glands you remove; must exclude before parathyroidectomy |
| Known bilateral RLN injury | Can be life-threatening [12] — bilateral vocal cord paralysis → airway obstruction; relative contraindication to further neck surgery |
| Undiagnosed phaeochromocytoma | Absolute contraindication to ANY elective surgery (thyroidectomy, parathyroidectomy, pancreatic surgery) in MEN2 until phaeo is excluded or treated |
| Pregnancy | Phaeochromocytoma surgery ideally deferred to 2nd trimester if possible; laparoscopic approach preferred; phenoxybenzamine crosses placenta but is used if needed; MRI preferred over CT for localisation |
| Unfit for surgery | Calcimimetics (e.g. cinacalcet): indicated when parathyroidectomy indicated but C/I surgery [1]; for phaeo: chronic alpha-blockade for medical management |
| Metastatic/inoperable pNETs | Medical treatment: buy time for surgery / unfit for surgery / metastatic disease [4] |
| Component | Follow-up Protocol |
|---|---|
| Post-thyroidectomy (MTC) | T4 replacement to keep euthyroid; serum calcitonin and CEA 6mo post-op then 6-12 monthly [5]; USG neck annually; CT/PET if calcitonin rising |
| Post-adrenalectomy (phaeo) | Annual plasma metanephrines (risk of contralateral phaeo developing later); if bilateral total → lifelong steroid replacement + Addisonian crisis education |
| Post-parathyroidectomy | Serum Ca, PTH annually; DEXA every 1-2 years; renal imaging if symptoms |
| Pituitary | MRI pituitary every 1-3 years; hormonal panel annually |
| Pancreatic NETs | Imaging (CT/MRI or EUS) every 1-3 years; tumour markers annually |
High Yield Summary
MEN2 Treatment Priority: Phaeo → MTC → PHPT (this order is non-negotiable)
Phaeochromocytoma:
- Pre-op: α-blockade (phenoxybenzamine) for 7-14 days → THEN β-blockade → volume expansion
- NEVER β before α (causes unopposed α → hypertensive crisis)
- Surgery: laparoscopic adrenalectomy; cortical-sparing preferred for bilateral MEN2 phaeo
- Post-op: watch for hypotension and rebound hypoglycaemia
MTC:
- Prophylactic thyroidectomy: Highest risk (MEN2B) = 1st year of life; High risk (codon 634) = by age 5; Moderate risk = guided by calcitonin
- Therapeutic: total thyroidectomy + central LN dissection
- Post-op: levothyroxine for euthyroid (NOT TSH suppression); calcitonin/CEA monitoring
- Advanced MTC: selpercatinib/pralsetinib (selective RET inhibitors) — a breakthrough in precision medicine
Hyperparathyroidism in MEN:
- MEN1: subtotal parathyroidectomy (3.5 glands) + cervical thymectomy; high recurrence (> 50% in 12y)
- MEN2A: only if symptomatic; NOT prophylactic; same surgical approach if needed
- Indications same as sporadic (CASR mnemonic): Ca ≥ 2.8, Age < 50, Skeletal T < -2.5, Renal CrCl < 60
MEN1 pNETs:
- Gastrinoma: medical (high-dose PPI) preferred over surgery due to multifocality
- Insulinoma: surgery for ALL patients
- Non-functioning: observe if < 2cm, resect if > 2cm or growing
Genetic cascade screening: Test all 1st-degree relatives; enables prophylactic thyroidectomy in MEN2 and early surveillance in MEN1.
Active Recall - Management of MEN Syndromes
References
[1] Senior notes: Ryan Ho Endocrine.pdf (pages 67, 132–133 — MEN1 and MEN2 management, phaeochromocytoma medical/surgical therapy, pituitary management) [2] Senior notes: felixlai.md (Etiology section — prophylactic thyroidectomy for MEN2) [3] Senior notes: maxim.md (Primary hyperparathyroidism — surgical indications CASR, focused PTHectomy vs BCE, subtotal PTHectomy technique, cervical thymectomy, complications, adrenalectomy approach and preparation) [4] Senior notes: maxim.md (Insulinoma — medical and surgical treatment, gastrinoma — medical and surgical management, pancreatic NET surgical approach) [5] Senior notes: Ryan Ho Endocrine.pdf (page 38 — MTC management, total thyroidectomy, calcitonin/CEA monitoring, prophylactic thyroidectomy) [6] Senior notes: Ryan Ho Endocrine.pdf (pages 100, 102 — pNET management principles, gastrinoma medical vs surgical, liver-directed therapy) [7] Senior notes: Ryan Ho Diagnostic Radiology.pdf (page 72 — MIBG, functional imaging tracers) [12] Senior notes: felixlai.md (Treatment section — surgical indications, contraindications including FHH and bilateral RLN injury, focused PTHectomy technique)
Complications of MEN Syndromes
MEN syndromes generate complications at three levels:
- Complications from the tumours themselves — hormone excess, mass effect, metastatic spread
- Complications from treatment — surgical morbidity, lifelong hormone replacement, drug side effects
- Complications unique to the genetic syndrome — recurrence, development of new tumours over a lifetime, psychological burden
Because MEN is a lifelong disease involving multiple organs, the complications are numerous and cumulative. Think of it as managing not one cancer, but a conveyor belt of tumours that keep appearing over decades. Let's systematically work through each category.
21. Complications of the Tumours Themselves (Disease Complications)
Chronic hypercalcaemia is the root cause of almost all PHPT complications. Remember: "bones, stones, abdominal moans, and psychic groans."
| Complication | Pathophysiology | Clinical Consequence |
|---|---|---|
| Nephrolithiasis | Chronically elevated filtered Ca²⁺ exceeds renal reabsorptive capacity → hypercalciuria → Ca²⁺ combines with oxalate or phosphate → calcium stone formation | Renal colic, haematuria, recurrent UTIs, obstruction |
| Nephrocalcinosis | Diffuse deposition of calcium salts in renal parenchyma → tubulointerstitial nephritis | Progressive CKD; may be irreversible |
| Osteoporosis / Osteitis fibrosa cystica | Chronic PTH excess → ↑osteoclast activity via RANKL upregulation → cortical bone resorption; severe cases show "brown tumours" (collections of osteoclasts and fibrous tissue) | Fragility fractures (vertebral, hip, distal radius); bone pain; subperiosteal resorption on X-ray (classically seen at radial aspect of 2nd/3rd phalanx) |
| Peptic ulcer disease | Hypercalcaemia stimulates gastrin secretion from G cells → ↑gastric acid → exacerbated further in MEN1 if gastrinoma is also present | Epigastric pain, GI bleeding, perforation |
| Acute pancreatitis | Ca²⁺ activates trypsinogen to trypsin within pancreatic duct → autodigestion; calcium also may precipitate in pancreatic ducts | Severe epigastric pain radiating to back, ↑amylase/lipase |
| Cardiac complications | Ca²⁺ accelerates cardiac repolarisation → shortened QTc; chronic hypercalcaemia → LVH, vascular calcification, hypertension | Arrhythmias, hypertension, LV dysfunction |
| Neuropsychiatric | Ca²⁺ affects neuronal membrane stability → reduced excitability → cognitive slowing | Depression, confusion, fatigue, psychosis ("psychic groans"); coma in severe hypercalcaemia |
| Hypercalcaemic crisis | Serum Ca > 3.5 mmol/L → acute renal failure, cardiac arrhythmias, coma | Medical emergency; requires aggressive IV saline, loop diuretics, bisphosphonates, calcitonin |
MEN-specific nuance: In MEN1, PHPT is virtually universal and has a high recurrence rate ( > 50% in 12 years if subtotal parathyroidectomy) [1] — meaning patients often face multiple reoperations with cumulative risk of surgical complications. In MEN2A, PHPT is usually mild and asymptomatic [1] and rarely causes these severe complications.
| Complication | Pathophysiology | Clinical Consequence |
|---|---|---|
| Local invasion | MTC is an aggressive malignancy that invades surrounding structures in the neck | Dysphagia (oesophageal compression/invasion), dyspnoea/stridor (tracheal invasion), hoarseness (RLN invasion → vocal cord paralysis) [12] |
| Lymph node metastasis | MTC metastasises early via lymphatics; level VI (central compartment) is the first echelon [8] | Palpable cervical lymphadenopathy; lateral neck disease indicates more advanced spread |
| Distant metastasis | Haematogenous spread to liver, lungs, bone, brain | Hepatomegaly, bone pain, pathological fractures, respiratory compromise |
| Secretory diarrhoea | Calcitonin directly stimulates intestinal Cl⁻ and H₂O secretion; also prostaglandins and other peptides secreted by MTC | Chronic, watery, non-bloody diarrhoea; can be debilitating; correlates with high tumour burden |
| Flushing | Vasoactive peptides (calcitonin, CGRP, prostaglandins) → peripheral vasodilation | Episodic facial flushing; mimics carcinoid syndrome |
| Ectopic Cushing's syndrome | Rarely, MTC secretes ectopic ACTH → adrenal cortisol hypersecretion | Weight gain, hyperglycaemia, hypertension, hypokalemia — ominous sign of advanced/dedifferentiated disease |
| Poor response to adjuvant therapy | MTC does NOT concentrate iodine (C cells lack NIS) and is relatively radioresistant; no good adjuvant Tx [5] | Unlike differentiated thyroid cancer, RAI ablation is useless; limited chemotherapy options until selective RET inhibitors |
MEN2B-specific: MTC in MEN2B is the most aggressive form [1]. It develops earliest (infancy) and metastasises earliest. If prophylactic thyroidectomy is missed in the first year of life, many patients already have metastatic disease by childhood.
Prognosis: 5y survival 60-70% for MTC overall [5]. This is significantly worse than differentiated thyroid cancer ( > 95% 5-year survival).
Phaeochromocytoma is the most acutely dangerous component of MEN2 because catecholamine excess can cause sudden death.
| Complication | Pathophysiology | Clinical Consequence |
|---|---|---|
| Hypertensive crisis | Massive catecholamine release → α₁ vasoconstriction → systolic BP > 250 mmHg; can be precipitated by surgery, anaesthesia, physical exertion, or certain drugs (TCA, metoclopramide, glucocorticoids) | Pheochromocytoma crisis: APO, ICH [3] — acute pulmonary oedema, intracranial haemorrhage |
| Catecholamine cardiomyopathy | Chronic catecholamine excess → direct myocardial toxicity (oxidative stress, calcium overload, contraction band necrosis) → dilated or Takotsubo-like cardiomyopathy | Heart failure, ↓ejection fraction; may be reversible after tumour removal |
| Myocardial infarction | Catecholamine-driven coronary vasospasm + ↑myocardial O₂ demand (from tachycardia + HTN) | Chest pain, troponin elevation, ST changes; can occur in young patients without atherosclerosis |
| Arrhythmias | Catecholamines → ↑automaticity and ↑conduction velocity; β₁-stimulation → triggered activity | Sinus tachycardia, SVT, VT, VF; can be fatal |
| Intracranial haemorrhage | Severe hypertension → rupture of cerebral vessels | Sudden severe headache, focal neurological deficit, coma; high mortality |
| Hypertensive retinopathy | Chronic HTN → arteriolar damage in retina | Grade I-IV retinopathy; papilloedema in malignant hypertension |
| Glucose intolerance / Diabetes | Catecholamines → ↑hepatic glycogenolysis/gluconeogenesis + ↓insulin secretion (via α₂ on β-cells) | Hyperglycaemia, new-onset diabetes |
| Malignant phaeochromocytoma | 8-13% malignant; defined not histologically but by local invasion or distal metastases [1]; histologically and biochemically indistinguishable from benign disease [3] | Metastases to bone, liver, lungs, lymph nodes; poor prognosis (5y survival 40% for malignant [1]) |
The Deadly Intraoperative Phaeo Crisis
The most feared complication is an undiagnosed phaeochromocytoma being discovered incidentally during surgery for another MEN2 component (e.g. thyroidectomy for MTC). Anaesthetic induction, intubation, and surgical manipulation can all trigger massive catecholamine release. Without prior α-blockade, this results in hypertensive crisis → arrhythmias → cardiac arrest → death. This is why the iron-clad rule exists: screen for phaeo FIRST before ANY surgery in MEN2.
| Complication | Pathophysiology | Clinical Consequence |
|---|---|---|
| Visual field defects | Macroadenoma (85% in MEN1 [1]) compresses the optic chiasm from below → damages the nasal (crossing) fibres | Bitemporal hemianopia; progressive visual loss if untreated; may be irreversible |
| Hypopituitarism | Mass effect compresses normal pituitary tissue | Sequential hormone loss: GH → LH/FSH → TSH → ACTH; can cause adrenal crisis if ACTH deficiency unrecognised |
| Pituitary apoplexy | Sudden haemorrhage or infarction within a pituitary adenoma | Thunderclap headache, acute visual loss, ophthalmoplegia (cavernous sinus compression), altered consciousness; neurosurgical emergency |
| Complications of prolactin excess | Galactorrhoea, hypogonadism, infertility; long-standing hyperprolactinaemia → osteoporosis (↓oestrogen/testosterone from GnRH suppression) | Amenorrhoea/infertility in women; erectile dysfunction in men; osteoporotic fractures |
| Complications of GH excess | Acromegaly → ↑CVD risk, DM, OSA, carpal tunnel syndrome, colonic polyps → ↑colorectal cancer risk | Premature cardiovascular death if untreated; ↑all-cause mortality 2-3× |
| Complications of ACTH excess | Cushing's disease → hypertension, diabetes, osteoporosis, immunosuppression, VTE | Opportunistic infections, pathological fractures, cardiovascular events |
| Tumour | Complication | Pathophysiology |
|---|---|---|
| Gastrinoma | Multiple PUD in unusual locations → bleeding, stricture, perforation [4][6]; chronic diarrhoea → malnutrition, B₁₂ deficiency | 4-6× gastric acid output → mucosal destruction; 60-90% malignant → liver metastases common [6] |
| Insulinoma | Recurrent severe hypoglycaemia → seizures, cognitive decline, death; neuroglycopenic brain damage | Autonomous insulin secretion → glucose < 2.5 mmol/L |
| VIPoma | Severe dehydration, hypokalaemia → cardiac arrhythmias, metabolic acidosis | Massive secretory diarrhoea (up to 5L/day) → electrolyte losses |
| Glucagonoma | DVT/PE (50%); necrolytic migratory erythema → skin breakdown and secondary infection; diabetes | Hypercoagulable state; amino acid/nutrient depletion → skin necrosis |
| Malignant transformation | Gastrinoma: 60-90% malignant; glucagonoma: 50-80% metastatic at diagnosis [6] | Liver metastases most common → hepatomegaly, liver failure; 10y survival 83% if no liver mets, 30% if liver mets present [6] |
| Condition | Complication | Notes |
|---|---|---|
| Thymic carcinoid (MEN1) | Aggressive malignancy; mediastinal mass → SVC obstruction, phrenic nerve palsy | More common in male smokers; poor prognosis even after resection; cervical thymectomy during parathyroidectomy may reduce risk [1] |
| Intestinal ganglioneuromas (MEN2B) | Chronic constipation, megacolon [1]; pseudo-obstruction → may require surgery; failure to thrive in children | Ganglion cell proliferation disrupts peristalsis → functional obstruction |
| Hirschsprung disease (MEN2A) | Neonatal intestinal obstruction, enterocolitis, perforation | RET loss-of-function in enteric neurons → aganglionosis → failure of peristalsis in affected bowel segment |
| Adrenocortical tumours (MEN1) | Usually non-functional; rarely Cushing's syndrome or Conn's syndrome | Up to 40% of MEN1 patients on imaging; most clinically insignificant |
22. Complications of Treatment (Iatrogenic Complications)
These are perhaps the most clinically important day-to-day complications because MEN patients undergo multiple surgeries over their lifetime.
Complications of thyroidectomy [12]:
| Timing | Complication | Mechanism | Management |
|---|---|---|---|
| Immediate | Intraoperative bleeding | Injury to superior/inferior thyroid arteries or tributaries | Meticulous surgical haemostasis |
| Immediate | Recurrent laryngeal nerve injury | RLN runs in the tracheoesophageal groove, intimately related to the inferior thyroid artery and Berry's ligament — at risk during dissection | Ipsilateral RLN injury → unilateral vocal cord palsy → hoarseness and ineffective cough [12]; bilateral RLN injury → bilateral vocal cord palsy → stridor and dyspnoea (airway obstruction) [12] — may require emergency intubation or tracheostomy |
| Immediate | Superior laryngeal nerve injury | External branch of SLN runs with the superior thyroid artery to supply the cricothyroid muscle | SLN injury → vocal fatigue and changes in voice quality [12] (loss of ability to produce high-pitched sounds — "can't sing high notes") |
| Early | Haematoma formation | Reactionary haemorrhage from thyroid bed → expanding neck haematoma | Potentially fatal if compression on airways → removal of sutures and allow drainage of blood [12]; may require return to theatre |
| Early | Wound infection | Surgical wound contamination | Antibiotics; wound care |
| Late | Hypoparathyroidism → hypocalcaemia | MOST common complication [12]; inadvertent removal or devascularisation of parathyroid glands during thyroidectomy | Symptoms: perioral and acral paraesthesia, carpopedal spasm, muscle spasms, Trousseau's sign, Chvostek's sign [12]; Fast replacement: IV 10-20 mL of 10% calcium gluconate over 10 mins; Maintenance: calcium carbonate + calcitriol [12] |
| Late | Hungry bone syndrome | After removal of a PTH-secreting tumour or parathyroid tissue during thyroidectomy → sudden ↓PTH → "hungry" demineralised bones rapidly take up Ca²⁺ from blood → profound hypocalcaemia | Check serum corrected Ca²⁺ level or PTH level postoperatively [12]; predicted by ↑ALP pre-op [3]; Mx: IV calcium + oral calcium + calcitriol |
| Late | Hypothyroidism | Expected consequence of total thyroidectomy → absent T4/T3 production | Lifelong levothyroxine replacement; target euthyroid state (normal TSH) for MTC (NOT suppressive) [1] |
| Late | Recurrence / Keloid | MTC recurrence (calcitonin monitoring); hypertrophic scarring at Kocher's incision | Regular calcitonin/CEA surveillance; scar management |
RLN Injury — The Surgeon's Nightmare
Bilateral RLN injury is the most feared complication of thyroidectomy. Both vocal cords are paralysed in the paramedian (adducted) position → the airway is nearly completely obstructed. The patient develops acute stridor and dyspnoea [12] immediately on extubation. This requires emergency re-intubation or tracheostomy. The risk is particularly relevant in MEN2 because patients undergo total thyroidectomy (both sides), and re-operative surgery for recurrent MTC further increases the risk due to scarring.
Specific complications [3]:
| Complication | Mechanism | Key Points |
|---|---|---|
| RLN injury | Same as thyroidectomy — RLN at risk during parathyroid exploration | Risk cumulative with repeated neck surgeries |
| Reactionary haemorrhage | Bleeding from parathyroid bed, venous ooze | Same management as post-thyroidectomy haematoma [3] |
| Hungry bone syndrome | Rapid, profound hypocalcaemia due to sudden drop in PTH, causing rapid deposition of Ca into demineralised bone [3] | More severe in patients with long-standing severe hyperparathyroidism and high pre-op ALP; Mx: Ca + vit D [3] |
| Transient hypocalcaemia | After focused parathyroidectomy: transient suppression of normal glands by adenoma [3] — the remaining glands were chronically suppressed and need time to "wake up" | Usually resolves in days to weeks; supportive Ca supplementation |
| Permanent hypoparathyroidism | Insufficient parathyroid remnant or devascularised tissue | Requiring Ca / vit D supplement 1 year post-op [3]; lifelong if no recovery |
| Persistent hyperparathyroidism (< 6 months) | Due to missed pathology [3] — inadequate resection, unrecognised multigland disease | Mx: bilateral cervical exploration (BCE) [3] |
| Recurrent hyperparathyroidism ( > 6 months) | Due to missed pathology, parathyromatosis (disseminated parathyroid tissue within soft tissue of neck/mediastinum due to rupture of parathyroid gland during operation) [3] | Mx: MIBI scan, BCE [3]; recurrence rate in MEN1 > 50% in 12 years [1] |
Why recurrence is so much higher in MEN:
- In sporadic PHPT, removing a single adenoma = cure in ~97%
- In MEN, all parathyroid tissue is genetically predisposed to hyperplasia → the remnant left behind during subtotal parathyroidectomy will eventually undergo hyperplasia again → recurrence is the rule, not the exception
- This is a fundamental tension in MEN1 parathyroid surgery: remove too little → recurrence; remove too much → permanent hypoparathyroidism
Postop Cx: HTN crisis, hypotension, rebound hypoGly → monitor BP, HR, H'stix closely postop [1]
| Complication | Mechanism | Management |
|---|---|---|
| Intra-operative hypertensive crisis | Haemodynamic instability (phaeochromocytoma) [3] — manipulation of tumour releases catecholamine bolus | IV phentolamine, nitroprusside; adequate pre-op α-blockade minimises risk |
| Post-operative hypotension | Sudden removal of catecholamine drive → vasodilation + depleted intravascular volume (chronic vasoconstriction → reduced plasma volume) | IV fluid resuscitation; pre-op volume expansion critical |
| Rebound hypoglycaemia | Catecholamines normally inhibit insulin secretion + promote glycogenolysis; post-tumour removal → loss of counter-regulatory hormones → unopposed insulin → hypoglycaemia | Monitor H'stix Q1-2h for 24h; IV dextrose if needed |
| Adrenal insufficiency | After bilateral adrenalectomy (common in MEN2 with bilateral phaeo) — loss of cortisol + aldosterone production | IV hydrocortisone upon removal of adrenal gland [3]; lifelong oral hydrocortisone + fludrocortisone replacement; Addisonian crisis education and MedicAlert bracelet |
| Injury to surrounding structures | Right adrenalectomy: IVC, right lobe of liver; Left adrenalectomy: pancreatic tail, spleen [3] | Careful surgical technique; may require conversion to open |
| Contralateral phaeo development | In MEN2, bilateral phaeo eventually develops in up to 50-100% → if initial surgery was unilateral, contralateral phaeo may appear years later | Lifelong annual plasma metanephrine surveillance; contralateral adrenalectomy when needed |
| Addisonian crisis risk | Post bilateral adrenalectomy: any physiological stress (infection, surgery, trauma) without adequate steroid supplementation → acute adrenal insufficiency | Sick-day rules: double/triple steroid dose during illness; emergency IM hydrocortisone kit; MedicAlert bracelet |
| Complication | Mechanism | Notes |
|---|---|---|
| Pancreatic fistula | Leakage of pancreatic juice from anastomosis or resection margin → enzymatic autodigestion of surrounding tissue | Most common complication of distal pancreatectomy; managed with drainage, octreotide, nutrition |
| Exocrine pancreatic insufficiency | Loss of pancreatic parenchyma → insufficient digestive enzyme production → fat/protein maldigestion | Steatorrhoea, weight loss; managed with pancreatic enzyme replacement (Creon) |
| Endocrine pancreatic insufficiency | Loss of islet mass → insulin deficiency | Post-pancreatectomy diabetes; managed with insulin |
| Post-Whipple complications | Bile leak, delayed gastric emptying, dumping syndrome, marginal ulceration | Complex post-operative management |
| Complication | Mechanism | Notes |
|---|---|---|
| Diabetes insipidus | Damage to posterior pituitary / pituitary stalk → ↓ADH → inability to concentrate urine | Polyuria, polydipsia; managed with desmopressin (DDAVP); may be transient or permanent |
| Hypopituitarism | Damage to anterior pituitary tissue during surgery | Sequential hormone deficiency requiring replacement (hydrocortisone, levothyroxine, sex hormones, GH) |
| CSF rhinorrhoea | Breach of sellar floor/arachnoid during transsphenoidal approach | Headache, watery nasal discharge; risk of meningitis; may require surgical repair |
| Meningitis | CSF leak → ascending infection | Fever, headache, nuchal rigidity; medical emergency |
| Recurrence | MEN1-associated pituitary adenomas are more aggressive and recurrence-prone than sporadic | Lifelong MRI surveillance every 1-3 years |
These are not complications of any single tumour but of the MEN syndrome as a whole.
| Complication | Explanation |
|---|---|
| Lifelong tumour risk | New tumours can develop at any point in life; patients must undergo annual surveillance forever — a major burden on both the patient and healthcare system |
| Cumulative surgical morbidity | Multiple neck operations (parathyroidectomy, thyroidectomy, re-operations for recurrence) → progressive scarring → ↑risk of RLN injury, hypoparathyroidism, and difficult re-operations with each subsequent surgery |
| Psychological burden | Chronic disease requiring lifelong surveillance, genetic anxiety (50% risk to each child), potential guilt about passing the mutation to offspring, uncertainty about which new tumour will develop next; ↑rates of anxiety and depression |
| Impact on reproductive planning | Autosomal dominant → 50% chance of transmission; raises complex decisions about prenatal genetic testing, preimplantation genetic diagnosis (PGD), or acceptance of risk |
| Overtreatment vs undertreatment dilemma | Too-aggressive surgery → permanent hypoparathyroidism, Addisonian crisis, diabetes; too-conservative approach → missed or metastatic tumour; finding the balance is a lifelong challenge |
| Diagnostic delay in de novo MEN2B | ~50% of MEN2B is de novo (no family history) → clinical recognition relies on phenotypic features (mucosal neuromas, Marfanoid habitus, constipation) that may be overlooked → late diagnosis → advanced MTC with poor prognosis |
| Syndrome | Overall Survival | Key Determinants |
|---|---|---|
| MEN1 | 64% overall 20-year survival [1] | Death usually from malignant pNET (gastrinoma liver metastases most common) or thymic carcinoid; not usually from PHPT |
| MEN2A | ~95% 10-year survival if MTC detected early; significantly worse if MTC has metastasised | Prognosis determined primarily by stage of MTC at diagnosis; phaeo rarely fatal if properly managed |
| MEN2B | Worst prognosis of all MEN subtypes | MTC in MEN2B is earliest onset and most aggressive; many patients have metastatic disease in childhood if prophylactic thyroidectomy is missed |
| Sporadic MTC | 5-year survival 60-70% [5] | Worse than differentiated thyroid cancer ( > 95%); MEN2-associated familial MTC (detected by screening) may have better prognosis than sporadic (detected when symptomatic) |
| Phaeochromocytoma | 5-year survival 95% for benign, 40% for malignant [1] | Malignancy defined by metastasis, not histology; MEN2-associated phaeo is less commonly malignant than sporadic |
| Gastrinoma | 10-year survival 83% if no liver mets, 30% if liver mets present [6] | Hepatic metastasis is the key prognostic determinant |
| Component | Disease Complications | Treatment Complications | MEN-Specific Issues |
|---|---|---|---|
| PHPT | Stones, bones, moans, groans; hypercalcaemic crisis | Hungry bone syndrome, RLN injury, permanent hypoparathyroidism | Recurrence > 50% in 12y (MEN1) |
| MTC | Local invasion, LN/distant mets, secretory diarrhoea | RLN injury (bilateral = airway emergency), hypothyroidism, hypoparathyroidism | No good adjuvant Tx; bilateral/multifocal |
| Phaeo | Hypertensive crisis, catecholamine cardiomyopathy, stroke, MI | Post-op hypotension, hypoglycaemia, Addisonian crisis (bilateral) | Contralateral phaeo may develop later |
| Pituitary | Visual loss, hypopituitarism, apoplexy | DI, CSF leak, meningitis, hormone deficiency | 85% macroadenoma, more aggressive |
| pNETs | Ulcer complications, hypoglycaemia, liver mets | Pancreatic fistula, endocrine/exocrine insufficiency | Multifocal → low surgical cure rate |
| Syndrome | — | — | Lifelong surveillance, psychological burden, reproductive implications, cumulative surgical morbidity |
High Yield Summary
Most dangerous acute complication: Undiagnosed phaeochromocytoma crisis — can be triggered by surgery, anaesthesia, or drugs → hypertensive emergency → APO, ICH, cardiac arrest, death.
Most common post-thyroidectomy complication: Hypoparathyroidism → hypocalcaemia (perioral paraesthesia, carpopedal spasm, Trousseau's/Chvostek's sign).
Bilateral RLN injury = airway emergency → stridor, dyspnoea → emergency tracheostomy.
Hungry bone syndrome: Profound post-op hypocalcaemia after parathyroidectomy; predicted by high pre-op ALP; Mx with IV and oral calcium + calcitriol.
MEN1 PHPT recurrence > 50% in 12 years after subtotal parathyroidectomy — lifelong Ca/PTH monitoring needed.
MEN2 phaeo is commonly bilateral (30-100%) → risk of Addisonian crisis after bilateral adrenalectomy → lifelong steroid replacement + sick-day rules.
MTC prognosis: 5-year survival 60-70%; no effective adjuvant therapy except selective RET inhibitors (selpercatinib/pralsetinib) for advanced disease.
MEN1 cause of death: Usually malignant pNET (gastrinoma with liver mets) or thymic carcinoid. 20-year survival 64%.
Key principle: MEN is not a single event — it's a lifelong genetic predisposition requiring annual multimodal surveillance, multiple surgeries, and management of cumulative treatment complications.
Active Recall - Complications of MEN Syndromes
References
[1] Senior notes: Ryan Ho Endocrine.pdf (pages 67, 132–133 — MEN1 and MEN2 complications, phaeo management and post-op complications, MTC prognosis, PHPT recurrence rate, pituitary macroadenoma percentage, 20-year survival) [2] Senior notes: felixlai.md (Etiology section — prophylactic thyroidectomy rationale) [3] Senior notes: maxim.md (Primary hyperparathyroidism — surgical complications: hungry bone syndrome, permanent hypoparathyroidism, persistent/recurrent PHPT, parathyromatosis; Adrenalectomy complications: haemodynamic instability, adrenal insufficiency, injury to surroundings; Phaeochromocytoma — malignant phaeo, phaeo crisis) [4] Senior notes: maxim.md (Gastrinoma — complications: peptic ulcer bleeding/perforation/stricture, liver metastases prognosis) [5] Senior notes: Ryan Ho Endocrine.pdf (page 38 — MTC prognosis 5-year survival 60-70%, no good adjuvant Tx, calcitonin/CEA monitoring) [6] Senior notes: Ryan Ho Endocrine.pdf (pages 100, 102 — pNET malignancy rates, gastrinoma prognosis 10y survival with and without liver mets) [8] Senior notes: Ryan Ho Fundamentals.pdf (page 426 — Level VI first site of metastasis, FHx of MTC/MEN2) [12] Senior notes: felixlai.md (Complications of thyroidectomy section — RLN injury, SLN injury, haematoma, hypoparathyroidism, hungry bone syndrome, thyroid storm; post-op Ca management)
Hypothyroidism
Hypothyroidism is a condition of insufficient thyroid hormone production by the thyroid gland, resulting in decreased metabolic activity and clinical features such as fatigue, weight gain, cold intolerance, and bradycardia.
Non-toxic/simple Goitre (inc. Retrosternal)
Non-toxic simple goitre is a diffuse or nodular enlargement of the thyroid gland without hyperthyroidism or hypothyroidism, which may extend retrosternally and cause compressive symptoms in the thoracic inlet.